US20200363436A1 - Methods of assessing future memory loss by measuring polyunsaturated fatty acids - Google Patents
Methods of assessing future memory loss by measuring polyunsaturated fatty acids Download PDFInfo
- Publication number
- US20200363436A1 US20200363436A1 US16/889,771 US202016889771A US2020363436A1 US 20200363436 A1 US20200363436 A1 US 20200363436A1 US 202016889771 A US202016889771 A US 202016889771A US 2020363436 A1 US2020363436 A1 US 2020363436A1
- Authority
- US
- United States
- Prior art keywords
- subject
- pufa
- influx
- pufas
- memory
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 title claims abstract description 116
- 238000000034 method Methods 0.000 title claims abstract description 90
- 208000000044 Amnesia Diseases 0.000 title description 2
- 208000026139 Memory disease Diseases 0.000 title description 2
- 230000006984 memory degeneration Effects 0.000 title description 2
- 208000023060 memory loss Diseases 0.000 title description 2
- 230000004941 influx Effects 0.000 claims abstract description 62
- 206010027175 memory impairment Diseases 0.000 claims abstract description 53
- 210000004556 brain Anatomy 0.000 claims abstract description 33
- 208000024827 Alzheimer disease Diseases 0.000 claims description 80
- 208000010877 cognitive disease Diseases 0.000 claims description 35
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 34
- 208000029028 brain injury Diseases 0.000 claims description 22
- 238000011282 treatment Methods 0.000 claims description 19
- 230000007423 decrease Effects 0.000 claims description 15
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 13
- 235000020778 linoleic acid Nutrition 0.000 claims description 13
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 13
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 7
- 238000012544 monitoring process Methods 0.000 claims description 7
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims description 6
- 229940012843 omega-3 fatty acid Drugs 0.000 claims description 5
- 239000006014 omega-3 oil Substances 0.000 claims description 5
- 235000020665 omega-6 fatty acid Nutrition 0.000 claims description 5
- 229940033080 omega-6 fatty acid Drugs 0.000 claims description 4
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 4
- 230000009529 traumatic brain injury Effects 0.000 claims 4
- 230000009514 concussion Effects 0.000 claims 2
- 238000012360 testing method Methods 0.000 abstract description 37
- 230000015654 memory Effects 0.000 description 60
- 239000002207 metabolite Substances 0.000 description 34
- 230000001149 cognitive effect Effects 0.000 description 27
- 238000004458 analytical method Methods 0.000 description 26
- 239000002131 composite material Substances 0.000 description 26
- 230000004907 flux Effects 0.000 description 26
- 210000002381 plasma Anatomy 0.000 description 22
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
- 238000010200 validation analysis Methods 0.000 description 19
- 230000013016 learning Effects 0.000 description 17
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 16
- 150000002632 lipids Chemical class 0.000 description 15
- 239000000090 biomarker Substances 0.000 description 12
- 235000014113 dietary fatty acids Nutrition 0.000 description 12
- 229930195729 fatty acid Natural products 0.000 description 12
- 239000000194 fatty acid Substances 0.000 description 12
- 150000004665 fatty acids Chemical class 0.000 description 12
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 11
- 230000014759 maintenance of location Effects 0.000 description 11
- 238000011952 auditory verbal learning test Methods 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 230000008449 language Effects 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 230000001419 dependent effect Effects 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 235000021342 arachidonic acid Nutrition 0.000 description 8
- 229940114079 arachidonic acid Drugs 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000001771 impaired effect Effects 0.000 description 8
- 238000002705 metabolomic analysis Methods 0.000 description 8
- 230000001755 vocal effect Effects 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 230000001431 metabolomic effect Effects 0.000 description 7
- 238000002552 multiple reaction monitoring Methods 0.000 description 7
- 230000008520 organization Effects 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 230000000007 visual effect Effects 0.000 description 7
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 6
- 230000006931 brain damage Effects 0.000 description 6
- 231100000874 brain damage Toxicity 0.000 description 6
- 230000019771 cognition Effects 0.000 description 6
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 6
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 6
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 6
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 6
- 238000007477 logistic regression Methods 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 150000003904 phospholipids Chemical class 0.000 description 6
- 230000008499 blood brain barrier function Effects 0.000 description 5
- 210000001218 blood-brain barrier Anatomy 0.000 description 5
- 238000002790 cross-validation Methods 0.000 description 5
- 229940090949 docosahexaenoic acid Drugs 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- 230000006996 mental state Effects 0.000 description 5
- 238000003908 quality control method Methods 0.000 description 5
- 238000007619 statistical method Methods 0.000 description 5
- 238000012034 trail making test Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 102100029470 Apolipoprotein E Human genes 0.000 description 4
- 101710095339 Apolipoprotein E Proteins 0.000 description 4
- 230000003930 cognitive ability Effects 0.000 description 4
- 230000006735 deficit Effects 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000003455 independent Effects 0.000 description 4
- 230000036542 oxidative stress Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 4
- 230000032258 transport Effects 0.000 description 4
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 description 3
- WRGQSWVCFNIUNZ-GDCKJWNLSA-N 1-oleoyl-sn-glycerol 3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O WRGQSWVCFNIUNZ-GDCKJWNLSA-N 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 3
- 206010012289 Dementia Diseases 0.000 description 3
- 235000021294 Docosapentaenoic acid Nutrition 0.000 description 3
- 108090001030 Lipoproteins Proteins 0.000 description 3
- 102000004895 Lipoproteins Human genes 0.000 description 3
- MEFKEPWMEQBLKI-AIRLBKTGSA-O S-adenosyl-L-methionine Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H]([NH3+])C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-O 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000000035 biogenic effect Effects 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- OKTJSMMVPCPJKN-BJUDXGSMSA-N carbon-11 Chemical compound [11C] OKTJSMMVPCPJKN-BJUDXGSMSA-N 0.000 description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 102000009543 guanyl-nucleotide exchange factor activity proteins Human genes 0.000 description 3
- 108040001860 guanyl-nucleotide exchange factor activity proteins Proteins 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000007334 memory performance Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 238000002600 positron emission tomography Methods 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 3
- 239000003643 water by type Substances 0.000 description 3
- SZQQHKQCCBDXCG-BAHYSTIISA-N (2e,4e,6e)-hexadeca-2,4,6-trienoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C(O)=O SZQQHKQCCBDXCG-BAHYSTIISA-N 0.000 description 2
- KXVFBCSUGDNXQF-DZDBOGACSA-N (2z,4z,6z,8z,10z)-tetracosa-2,4,6,8,10-pentaenoic acid Chemical compound CCCCCCCCCCCCC\C=C/C=C\C=C/C=C\C=C/C(O)=O KXVFBCSUGDNXQF-DZDBOGACSA-N 0.000 description 2
- HOBAELRKJCKHQD-UHFFFAOYSA-N (8Z,11Z,14Z)-8,11,14-eicosatrienoic acid Natural products CCCCCC=CCC=CCC=CCCCCCCC(O)=O HOBAELRKJCKHQD-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- GHCZAUBVMUEKKP-NHIHLBCISA-N 2-[[(4R)-4-[(3R,5S,7S,10S,13R,17R)-3,7-Dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]acetic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)C1C2C2CC[C@H]([C@@H](CCC(=O)NCC(O)=O)C)[C@@]2(C)CC1 GHCZAUBVMUEKKP-NHIHLBCISA-N 0.000 description 2
- OTLNPYWUJOZPPA-UHFFFAOYSA-N 4-nitrobenzoic acid Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C=C1 OTLNPYWUJOZPPA-UHFFFAOYSA-N 0.000 description 2
- OQOCQFSPEWCSDO-JLNKQSITSA-N 6Z,9Z,12Z,15Z,18Z-Heneicosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCC(O)=O OQOCQFSPEWCSDO-JLNKQSITSA-N 0.000 description 2
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 2
- 206010054089 Depressive symptom Diseases 0.000 description 2
- 235000021298 Dihomo-γ-linolenic acid Nutrition 0.000 description 2
- OPGOLNDOMSBSCW-CLNHMMGSSA-N Fursultiamine hydrochloride Chemical compound Cl.C1CCOC1CSSC(\CCO)=C(/C)N(C=O)CC1=CN=C(C)N=C1N OPGOLNDOMSBSCW-CLNHMMGSSA-N 0.000 description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 2
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 2
- 102000015439 Phospholipases Human genes 0.000 description 2
- 108010064785 Phospholipases Proteins 0.000 description 2
- JQOHKCDMINQZRV-WDSKDSINSA-N Pro-Asn Chemical compound NC(=O)C[C@@H](C([O-])=O)NC(=O)[C@@H]1CCC[NH2+]1 JQOHKCDMINQZRV-WDSKDSINSA-N 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- AHANXAKGNAKFSK-PDBXOOCHSA-N all-cis-icosa-11,14,17-trienoic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCCCC(O)=O AHANXAKGNAKFSK-PDBXOOCHSA-N 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000000117 blood based biomarker Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 229940106189 ceramide Drugs 0.000 description 2
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 2
- 239000000544 cholinesterase inhibitor Substances 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- JWPGJSVJDAJRLW-UHFFFAOYSA-N debrisoquin Chemical compound C1=CC=C2CN(C(=N)N)CCC2=C1 JWPGJSVJDAJRLW-UHFFFAOYSA-N 0.000 description 2
- 229960004096 debrisoquine Drugs 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- HOBAELRKJCKHQD-QNEBEIHSSA-N dihomo-γ-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O HOBAELRKJCKHQD-QNEBEIHSSA-N 0.000 description 2
- 230000003467 diminishing effect Effects 0.000 description 2
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- -1 e.g. Proteins 0.000 description 2
- IQLUYYHUNSSHIY-HZUMYPAESA-N eicosatetraenoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C=C\C=C\C(O)=O IQLUYYHUNSSHIY-HZUMYPAESA-N 0.000 description 2
- PRHHYVQTPBEDFE-UHFFFAOYSA-N eicosatrienoic acid Natural products CCCCCC=CCC=CCCCCC=CCCCC(O)=O PRHHYVQTPBEDFE-UHFFFAOYSA-N 0.000 description 2
- 238000000132 electrospray ionisation Methods 0.000 description 2
- 235000004626 essential fatty acids Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000009760 functional impairment Effects 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- OQOCQFSPEWCSDO-UHFFFAOYSA-N heneicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCCC(O)=O OQOCQFSPEWCSDO-UHFFFAOYSA-N 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 229960004502 levodopa Drugs 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 230000007787 long-term memory Effects 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 238000000491 multivariate analysis Methods 0.000 description 2
- 230000003959 neuroinflammation Effects 0.000 description 2
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 150000003905 phosphatidylinositols Chemical class 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- JIWBIWFOSCKQMA-UHFFFAOYSA-N stearidonic acid Natural products CCC=CCC=CCC=CCC=CCCCCC(O)=O JIWBIWFOSCKQMA-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000004885 tandem mass spectrometry Methods 0.000 description 2
- 102000013498 tau Proteins Human genes 0.000 description 2
- 108010026424 tau Proteins Proteins 0.000 description 2
- 229960003080 taurine Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- GHCZAUBVMUEKKP-UHFFFAOYSA-N ursodeoxycholic acid glycine-conjugate Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCC(O)=O)C)C1(C)CC2 GHCZAUBVMUEKKP-UHFFFAOYSA-N 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- XSXIVVZCUAHUJO-AVQMFFATSA-N (11e,14e)-icosa-11,14-dienoic acid Chemical compound CCCCC\C=C\C\C=C\CCCCCCCCCC(O)=O XSXIVVZCUAHUJO-AVQMFFATSA-N 0.000 description 1
- DVSZKTAMJJTWFG-SKCDLICFSA-N (2e,4e,6e,8e,10e,12e)-docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O DVSZKTAMJJTWFG-SKCDLICFSA-N 0.000 description 1
- HPSWUFMMLKGKDS-DNKOKRCQSA-N (2e,4e,6e,8e,10e,12e)-tetracosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCCCC\C=C\C=C\C=C\C=C\C=C\C=C\C(O)=O HPSWUFMMLKGKDS-DNKOKRCQSA-N 0.000 description 1
- AVKOENOBFIYBSA-WMPRHZDHSA-N (4Z,7Z,10Z,13Z,16Z)-docosa-4,7,10,13,16-pentaenoic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O AVKOENOBFIYBSA-WMPRHZDHSA-N 0.000 description 1
- YHGJECVSSKXFCJ-KUBAVDMBSA-N (6Z,9Z,12Z,15Z,18Z,21Z)-tetracosahexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCC(O)=O YHGJECVSSKXFCJ-KUBAVDMBSA-N 0.000 description 1
- TWSWSIQAPQLDBP-CGRWFSSPSA-N (7e,10e,13e,16e)-docosa-7,10,13,16-tetraenoic acid Chemical compound CCCCC\C=C\C\C=C\C\C=C\C\C=C\CCCCCC(O)=O TWSWSIQAPQLDBP-CGRWFSSPSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 description 1
- HVGRZDASOHMCSK-UHFFFAOYSA-N (Z,Z)-13,16-docosadienoic acid Natural products CCCCCC=CCC=CCCCCCCCCCCCC(O)=O HVGRZDASOHMCSK-UHFFFAOYSA-N 0.000 description 1
- GBNPCIWXLWZJGA-IGBSIYCFSA-N 1-O-octadecyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCCOC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC GBNPCIWXLWZJGA-IGBSIYCFSA-N 0.000 description 1
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 1
- LRYZPFWEZHSTHD-HEFFAWAOSA-O 2-[[(e,2s,3r)-2-formamido-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical class CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](NC=O)COP(O)(=O)OCC[N+](C)(C)C LRYZPFWEZHSTHD-HEFFAWAOSA-O 0.000 description 1
- SLAMLWHELXOEJZ-UHFFFAOYSA-N 2-nitrobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1[N+]([O-])=O SLAMLWHELXOEJZ-UHFFFAOYSA-N 0.000 description 1
- GZJLLYHBALOKEX-UHFFFAOYSA-N 6-Ketone, O18-Me-Ussuriedine Natural products CC=CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O GZJLLYHBALOKEX-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 1
- 235000017647 Brassica oleracea var italica Nutrition 0.000 description 1
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000555825 Clupeidae Species 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 235000021292 Docosatetraenoic acid Nutrition 0.000 description 1
- 235000021297 Eicosadienoic acid Nutrition 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 101000736368 Homo sapiens PH and SEC7 domain-containing protein 4 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 108010022337 Leucine Enkephalin Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 238000007476 Maximum Likelihood Methods 0.000 description 1
- 102100036232 PH and SEC7 domain-containing protein 4 Human genes 0.000 description 1
- 101710096328 Phospholipase A2 Proteins 0.000 description 1
- 102100026918 Phospholipase A2 Human genes 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 241001417524 Pomacanthidae Species 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- 241000277331 Salmonidae Species 0.000 description 1
- 241000269821 Scombridae Species 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- DJJCXFVJDGTHFX-UHFFFAOYSA-N Uridinemonophosphate Natural products OC1C(O)C(COP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-UHFFFAOYSA-N 0.000 description 1
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 1
- 240000000851 Vaccinium corymbosum Species 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- TWSWSIQAPQLDBP-UHFFFAOYSA-N adrenic acid Natural products CCCCCC=CCC=CCC=CCC=CCCCCCC(O)=O TWSWSIQAPQLDBP-UHFFFAOYSA-N 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 239000003012 bilayer membrane Substances 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 235000021014 blueberries Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 238000010224 classification analysis Methods 0.000 description 1
- 238000007621 cluster analysis Methods 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000003931 cognitive performance Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000004807 desolvation Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- CVCXSNONTRFSEH-UHFFFAOYSA-N docosa-2,4-dienoic acid Chemical compound CCCCCCCCCCCCCCCCCC=CC=CC(O)=O CVCXSNONTRFSEH-UHFFFAOYSA-N 0.000 description 1
- KAUVQQXNCKESLC-UHFFFAOYSA-N docosahexaenoic acid (DHA) Natural products COC(=O)C(C)NOCC1=CC=CC=C1 KAUVQQXNCKESLC-UHFFFAOYSA-N 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 235000020988 fatty fish Nutrition 0.000 description 1
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
- 229960002297 fenofibrate Drugs 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 238000004401 flow injection analysis Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000002599 functional magnetic resonance imaging Methods 0.000 description 1
- 229960003980 galantamine Drugs 0.000 description 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000021384 green leafy vegetables Nutrition 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000004750 isotope dilution mass spectroscopy Methods 0.000 description 1
- URLZCHNOLZSCCA-UHFFFAOYSA-N leu-enkephalin Chemical compound C=1C=C(O)C=CC=1CC(N)C(=O)NCC(=O)NCC(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=CC=C1 URLZCHNOLZSCCA-UHFFFAOYSA-N 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 230000004322 lipid homeostasis Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 238000011551 log transformation method Methods 0.000 description 1
- 238000009593 lumbar puncture Methods 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 235000020640 mackerel Nutrition 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- 230000007087 memory ability Effects 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 235000021288 n-6 DPA Nutrition 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000000092 prognostic biomarker Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 229960002429 proline Drugs 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 235000019512 sardine Nutrition 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000006403 short-term memory Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- RZHACVKGHNMWOP-ZWZRQGCWSA-N tetracosatetraenoic acid n-6 Chemical compound CCCCCCCCCCCCCCC\C=C\C=C\C=C\C=C\C(O)=O RZHACVKGHNMWOP-ZWZRQGCWSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008448 thought Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- DJJCXFVJDGTHFX-XVFCMESISA-N uridine 5'-monophosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 DJJCXFVJDGTHFX-XVFCMESISA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000031836 visual learning Effects 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Definitions
- the present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment.
- the methods comprise determining the influx of polyunsaturated fatty acids (PUFAs) into the brain from plasma in a test subject and comparing this measured influx to a normal standard influx.
- An increase in influx of PUFAs from the plasma into the brain is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.
- AD Alzheimer's disease
- AD is a neurodegenerative disorder characterized by a progressive dementia that insidiously and inexorably robs older adults of their memory and other cognitive abilities.
- the prevalence of AD is expected to double every 20 years from 35.6 million individuals worldwide in 2010 to 115 million affected individuals by 2050. There is no cure and current therapies are unable to slow the disease progression.
- Biomarkers for early disease including cerebrospinal fluid (CSF) tau and A ⁇ levels, structural and functional magnetic resonance imaging (MRI), and the recent use of brain amyloid imaging, are of limited use for widespread screening since they provide diagnostic options that are either invasive, i.e., require lumbar puncture, time-consuming, i.e., several hours in a scanner for most comprehensive imaging protocols, or expensive.
- No current blood-based biomarkers can detect incipient dementia with the required sensitivity and specificity at a preclinical stage.
- Continued interest in blood-based biomarkers remains because these specimens are obtained using rapid, minimally invasive methods.
- the comprehensive bioinformatic analyses of prognostic biomarkers may yield new insights into the underlying mechanisms and pathobiological networks of AD and possibly herald the development of new therapeutic strategies.
- MCI mild cognitive impairment
- AD mild cognitive impairment
- MCI or AD The preclinical interval resulting in mild cognitive impairment (MCI) or AD is known to be variable, multifactorial, and extends up to 7-10 years prior to the emergence of clinical signs.
- MCI mild cognitive impairment
- AD multimodal neurocognitive testing remains the most accurate, standardized, and widely used pre-mortem screening method to determine clinical MCI or AD.
- the utility of strict cognitive assessment for preclinical states of MCI or AD is limited, however, as this approach is time-consuming and expected to be present almost all individuals as normal, as it quantitatively delineates specific brain properties, such as language, thought, and behavior, which is typically not affected in individual in the preclinical state.
- a diagnostic method that is quick, effective, less invasive and accurate in determining future onset of MCI and/or AD.
- the present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment.
- the methods comprise determining the influx of polyunsaturated fatty acids (PUFAs) into the brain from plasma in a test subject and comparing this measured influx to a normal standard influx.
- An increase in influx of PUFAs from the plasma into the brain is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.
- FIG. 1 depicts a schematic representation of potential alterations within brain and peripheral blood responsible for reduced plasma phospholipid levels.
- 1 A shows a theoretical qualitative dot plot of differential changes occurring in cognitively normal control (NC), cognitively normal Converter pre (Cpre) subjects, and those with amnestic mild cognitive impairment or Alzheimer's disease (a MCI/AD). Note that all four processes are at the zero relative level in the NC subjects. Going from left to right, the first dot is the levels of PUFA influx into the brain; the second dot is levels of plasma PUFAs, the third dot is level of active neuroinflammation and the last dot on the right is the degree of brain injury.
- NC cognitively normal control
- Cpre cognitively normal Converter pre
- a MCI/AD amnestic mild cognitive impairment or Alzheimer's disease
- the Cpre subjects show significant transport of polyunsaturated fatty acid (PUFA) into the brain, likely to replenish lost substrate from inflammation, oxidative stress or other brain injury or metabolic abnormality.
- the increase in PUFA flux into the brain is an attempt to compensate for ongoing injury and results in a marked reduction in the plasma levels of molecules carrying those lipid species.
- 1 B. shows qualitative depiction of plasma phospholipid biomarker results previously quantified and specified (Mapstone et al., 2014, Fiandaca, et al., Alzheimer's & Dementia 10 (2014) S196-S212). Dark horizontal line within boxes represents proposed mean levels of metabolites for the group.
- FIG. 2 depicts the performance of the Preclinical Alzheimer's Disease Index (PADI).
- FIG. 2B depicts the survival analysis of baseline PADI on accumulative MCI/AD cases over 5 years adjusting for age, years of education, APOE4 carrier, global cognition, depression, and memory complaints.
- PADI Preclinical Alzheimer's Disease Index
- the present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment.
- the methods comprise determining the influx of polyunsaturated fatty acids (PUFAs) into the brain from plasma in a test subject and comparing this measured influx to a normal standard influx.
- An increase in influx of PUFAs from the plasma into the brain is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.
- test subject indicates a mammal, in particular a human or non-human primate.
- the test subject may or may not be in need of an assessment of a predisposition to memory impairment.
- the test subject may have a condition or may have been exposed to injuries or conditions that are associated with memory impairment prior to applying the methods of the present invention.
- the test subject has not been identified as a subject that may have a condition or may have been exposed to injuries or conditions that are associated with memory impairment prior to applying the methods of the present invention.
- the phrase “memory impairment” means a measureable or perceivable decline or decrease in the subject's ability to recall past events.
- the term “past events” includes both recent (new) events (short-term memory) or events further back in time (long-term memory).
- the methods are used to assess an increased risk for short-term memory impairment.
- the methods are used to assess an increased risk for long-term memory impairment.
- the measureable or perceivable decline in the subject's ability to recall past events may be assessed clinically by a health care provider, such as a physician, physician's assistant, nurse, nurse practitioner, psychologist, psychiatrist, hospice provider, or any other provider that can assess a subject's memory.
- the measureable or perceivable decline in the subject's ability to recall past events may be assessed in a less formal, non-clinical manner, including but not limited to the subject himself or herself, acquaintances of the subject, employers of the subject and the like.
- the invention is not limited to a specific manner in which the subject's ability to recall a past event is assessed.
- the methods of the invention can be implemented without the need to assess a subject's ability to recall past events.
- the methods of the present invention may also include assessing the subject's ability to assess past events one or more times, both before determining the subject's influx levels and after determining the subject's influx levels at least one time.
- the methods may also comprise assessing the individual's Preclinical Alzheimer's Disease Index (PADI).
- PADI is an assessment of an individual's likelihood of developing memory impairment based on a novel, synthetic scoring valuation comprising a memory component and an attention component.
- the PADI of the individual is assessed prior to determining the subject's PUFA profile and the PUFA profile is then used to further stratify subjects that are considered at risk of suffering from memory impairment based on the PADI.
- the PADI of the individual is assessed after determining the subject's PUFA profile and the PADI is then used to further stratify subjects that are considered at risk of suffering from memory impairment based on the PUFA profile.
- the PADI profile and the PUFA profile are assessed in conjunction with one another such that the combined composite profile is determined prior to any initial patient population stratification.
- the PADI is calculated as a simple ratio between attention performance evaluations and memory performance evaluations. In one embodiment, the PADI is calculated as a weighted ratio between attention performance evaluations and memory performance evaluations. In specific embodiments, the attention component is weighted less than the memory component in calculating the PADI, i.e., the value of the attention is component less than 1:1, i.e., between about 0.001 and about 0.499. In more specific embodiments, the attention component is weighted between about 0.499 about 0.200, between about 0.490 and about 0.300 and between about 0.485 and about 0.400.
- the memory component is weighted more than the attention component in calculating the PADI, i.e., the value of the attention component is more than 1:1, i.e., between about 0.501 and about 0.999.
- the memory component is weighted between about 0.501 and 0.800, between about 0.510 and about 0.700 and between about 0.515 and about 0.600.
- the signs of relative weights in determining the ratios could be reversed for each component, e.g., the weight of the attention component could be between ⁇ 0.001 and ⁇ 0.500 and the weight of the memory component could be between about ⁇ 0.0500 and ⁇ 0.999 such that the “higher” PADI score indicates that the subject has a higher risk of suffering from memory impairment.
- PUFA profile means the combination of a subject's PUFAs found in the peripheral blood or portions thereof, such as but not limited to plasma or serum.
- the PUFA profile is a collection of measurements, such as but not limited to a quantity or concentration, for individual metabolites taken from a test sample of the subject.
- test samples or sources of components for the PUFA profile include, but are not limited to, biological fluids, which can be tested by the methods of the present invention described herein, and include but are not limited to whole blood, such as but not limited to peripheral blood, serum, plasma, cerebrospinal fluid, urine, amniotic fluid, lymph fluids, and various external secretions of the respiratory, intestinal and genitourinary tracts, tears, saliva, milk, white blood cells, myelomas and the like.
- Test samples to be assayed also include but are not limited to tissue specimens including normal and abnormal tissue.
- the subject's PUFA profile is combined with the subject's PADI to provide a composite score for assessing the risk that the subject will suffer from future memory impairment.
- select embodiments of the methods of the present invention comprise obtaining a PUFA profile, obtaining a PADI and combining each of the profiles to obtain a composite profile having a performance component and a biological component.
- the composite profile is calculated as a simple ratio between the PADI and the PUFA profile. In one embodiment, the composite profile is calculated as a weighted ratio between the PADI and the PUFA profile. In specific embodiments, the PADI component is weighted less than the PUFA component in calculating the composite profile, i.e., the value of the PADI component is less than 1:1, i.e., between about 0.001 and about 0.499. In more specific embodiments, the PADI component is weighted between about 0.499 about 0.200, between about 0.490 and about 0.300 and between about 0.485 and about 0.400.
- the PADI component is weighted more than the PUFA component in calculating the composite profile, i.e., the value of the PADI component is more than 1:1, i.e., between about 0.501 and about 0.999.
- the PADI component is weighted between about 0.501 and 0.800, between about 0.510 and about 0.700 and between about 0.515 and about 0.600.
- the PUFA component is weighted more than the PADI component in calculating the composite, i.e., the value of the PADI component is more than 1:1, i.e., between about 0.501 and about 0.999.
- the PUFA component is weighted between about 0.501 and 0.800, between about 0.510 and about 0.700 and between about 0.515 and about 0.600.
- the PUFA component is weighted less than the PADI component in calculating the composite profile, i.e., the value of the PUFA component is less than 1:1, i.e., between about 0.001 and about 0.499.
- the PUFA component is weighted between about 0.499 about 0.200, between about 0.490 and about 0.300 and between about 0.485 and about 0.400.
- the signs of relative weights in determining the composite could be reversed for each component, e.g., the weight of the PADI component could be between ⁇ 0.001 and ⁇ 0.500 and the weight of the PUFA component could be between about ⁇ 0.0500 and ⁇ 0.999 such that the “higher” composite profile indicates that the subject has a higher risk of suffering from memory impairment.
- the decline or decrease in the ability to recall past events is relative to each individual's ability to recall past events prior to the diagnosed decrease or decline in the ability to recall past events. In another embodiment, the decline or decrease in the ability to recall past events is relative to a population's (general, specific or stratified) ability to recall past events prior to the diagnosed decrease or decline in the ability to recall past events.
- the term means “increased risk” is used to mean that the test subject has an increased chance of developing or acquiring memory impairment compared to a normal individual.
- the increased risk may be relative or absolute and may be expressed qualitatively or quantitatively.
- an increased risk may be expressed as simply determining the subject's PUFA flux levels and placing the patient in an “increased risk” category, based upon previous PUFA flux population studies.
- a numerical expression of the subject's increased risk may be determined based upon the measured PUFA flux levels.
- examples of other expressions of an increased risk include but are not limited to, odds, probability, odds ratio, p-values, attributable risk, relative frequency, positive predictive value, negative predictive value, and relative risk.
- the brain While the brain has the capacity to generate all of the lipid species it requires for normal function, in addition to most saturated and mono-unsaturated fatty acids, the substrates required for such independent maintenance of brain lipid homeostasis, especially sources of energy and PUFAs, are delivered via the bloodstream. In normal brain processing, lipid precursor components are recycled and have relatively long half-lives, especially certain fatty acid components of phospholipids (Edmond, 2001).
- Some PUFAs such as docosahaxaenoic acid (DHA; 22:6 n-3) and arachidonic acid (AA; 20:4 n-6) provide structural functionality as phospholipid components in bilayer membranes and, once released, either directly or through byproducts, participate in signal transduction processes with both positive and negative consequences within cells.
- DHA docosahaxaenoic acid
- AA arachidonic acid
- Such precursors exist in plasma as unesterified fatty acids (FAs) 22 carbons) bound to albumin, or as esterified FA components (>22 carbons) incorporated into circulating phospholipid species preferentially transported within lipoproteins.
- Triacylglycerols, diacylglycerophospholipids and lysophosphoglycerophospholipids represent major circulating esterified forms.
- Certain lysophosphatidylcholine species appear to be more efficiently transported into the brain from plasma compared to triacylglycerol or unesterified fatty acids (Lagarde et al., 2001).
- Esterified FAs are typically converted to unesterified forms by lipases within the lipoproteins or within the blood, prior to their passage (or flux) into the brain.
- BBB blood-brain barrier
- the fatty acids are polyunsaturated fatty acids (PUFAs).
- the PUFAs used in the methods of the present invention are omega-3 fatty acids and/or omega-6 fatty acids.
- the PUFAs for which influx is measured are essential fatty acids.
- Omega-3 PUFAs include but are not limited to Hexadecatrienoic acid (HTA), Alpha-linolenic acid (ALA), Stearidonic acid (SDA), Eicosatrienoic acid (ETE), Eicosatetraenoic acid (ETA), Eicosapentaenoic acid (EPA), Heneicosapentaenoic acid (HPA), Docosapentaenoic acid (DPA) Docosahexaenoic acid (DHA), Tetracosapentaenoic acid and Tetracosahexaenoic acid (Nisinic acid).
- the influx of any one or more of the omega-3 fatty acids listed herein can be used in any of the methods of the present invention.
- Omega-6 PUFAs include but are not limited to Linoleic acid (LA), Gamma-linolenic acid (GLA), Eicosadienoic acid, Dihomo-gamma-linolenic acid (DGLA), Arachidonic acid (AA), Docosadienoic acid, Adrenic acid, Docosapentaenoic acid (Osbond acid), Tetracosatetraenoic acid and Tetracosapentaenoic acid.
- the influx of any one or more of the omega-6 fatty acids listed herein can be used in any of the methods of the present invention.
- the PUFAs used in the methods of the present invention are the essential fatty acids alpha linolenic acid (ALA) or linoleic acid (LA). In another embodiment, both ALA and LA are used in the methods of the present invention.
- the PUFAs used in the methods of the present invention are EPA, DHA and/or AA.
- EPA and DHA are used in the methods of the present invention.
- AA and DHA are used in the methods of the present invention.
- EPA and AA are used in the methods of the present invention.
- AA, EPA and DHA are used in the methods of the present invention.
- the PUFAs can be labeled and then administered to the subject. Current methods and equipment can then be used to trace and monitor the movement of the labeled PUFAs from the circulation into the brain (“influx”) of the subject.
- influx refers to the movement of a molecule, such as a labeled PUFA, into the brain and across the blood brain barrier of a subject, such that the labeled PUFA would no longer be considered as being in the general circulation.
- Routes of administration of the labeled PUFAs are well known and include oral, nasal, intravenous injection, intramuscular injection, intraperitoneal injection and the like. The methods of the present invention are not limited to the routes of administration of the labeled PUFA.
- the PUFAs used in the methods of the present invention are labeled using a radioactive isotope.
- the Carbon-11 (11C) isotope can be used to label the PUFAs to be measured, by incorporating 11C into any of the PUFA carbon atoms.
- the carboxyl carbon ( ⁇ 1) or adjacent carbon ( ⁇ 2) would be tagged and allow that specific molecule to be monitored via positron emission tomography (PET) scanning as it migrates from blood to brain.
- PET positron emission tomography
- the chemical tagging of PUFAs with 11C is a known method for physiological monitoring and along with PET scanning to allow determination of flux of 11C-tagged substances into the brain.
- the labeled PUFAs can be monitored using equipment designed to detect and trace the label. For example, if the PUFAs are labeled using Carbon-11, which decay via positron emission, the influx of the labeled PUFAs can be measured using well-known positron emission tomography (PET) techniques. In another example, if the PUFAs are labeled with a fluorescent dye, e.g., BODIPYTM (4,4-difluoro-3a,4adiaza-s-indacene), the influx of the labeled PUFAs can be measured using in vivo fluorescent microscopy.
- a fluorescent dye e.g., BODIPYTM (4,4-difluoro-3a,4adiaza-s-indacene
- the attributable risk can also be used to express an increased risk.
- the AR describes the proportion of individuals in a population exhibiting memory impairment due to a certain minimum or maximum influx level.
- the public health relevance of the AR measurement lies in estimating the proportion of cases of memory impairment in the population that could be prevented if the influx levels were not abnormal.
- RR is the relative risk, which can be approximated with the odds ratio when the influx levels under study have a relatively low incidence in the general population.
- the increased risk of a patient can be determined from p-values that are derived from association studies. Specifically, associations with specific PUFA flux levels can be performed using regression analysis by regressing the PUFA flux levels with memory impairment. In addition, the regression may or may not be corrected or adjusted for one or more factors.
- the factors for which the analyses may be adjusted include, but are not limited to age, sex, weight, ethnicity, geographic location, fasting state, state of pregnancy or post-pregnancy, menstrual cycle, general health of the subject, alcohol or drug consumption, caffeine or nicotine intake and circadian rhythms, and the subject's apolipoprotein epsilon (ApoE) genotype to name a few.
- Increased risk can also be determined from p-values that are derived using logistic regression.
- Binomial (or binary) logistic regression is a form of regression that is used when the dependent is a dichotomy and the independents are of any type.
- Logistic regression can be used to predict a dependent variable on the basis of continuous and/or categorical independents and to determine the percent of variance in the dependent variable explained by the independents; to rank the relative importance of independents; to assess interaction effects; and to understand the impact of covariate control variables.
- Logistic regression applies maximum likelihood estimation after transforming the dependent into a “logit” variable (the natural log of the odds of the dependent occurring or not). In this way, logistic regression estimates the probability of a certain event occurring.
- SAS statistical analysis software
- Statistical analysis software is a general purpose package (similar to Stata and SPSS) created by Jim Goodnight and N.C. State University colleagues. Ready-to-use procedures handle a wide range of statistical analyses, including but not limited to, analysis of variance, regression, categorical data analysis, multivariate analysis, survival analysis, psychometric analysis, cluster analysis, and nonparametric analysis.
- select embodiments of the present invention comprise the use of a computer comprising a processor and the computer is configured or programmed to generate one or more PUFA profiles and/or to determine statistical risk.
- the methods may also comprise displaying the one or more profiles and/or risk profiles on a screen that is communicatively connected to the computer.
- two different computers can be used: one computer configured or programmed to generate one or more PUFA profiles and a second computer configured or programmed to determine statistical risk. Each of these separate computers can be communicatively linked to its own display or to the same display.
- the assessment for flux of the one or more PUFAs can be expressed as absolute or relative values and may or may not be expressed in relation to another component, a standard an internal standard or another molecule of compound known to be in the sample. If flux is assessed as relative to a standard or internal standard, the standard may be added to the test sample prior to, during or after sample processing.
- the subject's flux measurement(s) is(are) compared to flux measurements deemed to be normal.
- an individual or group of individuals may be first assessed for their ability to recall past events to establish that the individual or group of individuals has a normal or acceptable ability memory. Such individuals would be followed serially in a longitudinal study that documents their lack of development of memory disturbances over at least a 5-year period. Such stable cognitive status and the correlated PUFA flux levels taken serially over this time in the individual or group of individuals would establish a “normal PUFA flux level.”
- normal flux levels can be ascertained from the same subject when the subject is deemed to possess normal cognitive abilities and no signs (clinical or otherwise) of memory impairment.
- normal flux levels are assessed in the same subject from whom the sample is taken prior to the onset of measureable, perceivable or diagnosed memory impairment. That is, the term “normal” with respect to PUFA flux can be used to mean the subject's baseline PUFA flux prior to the onset of memory impairment. The PUFA flux levels can then be reassessed serially and compared to either the subject's baseline PUFA flux level, or to the mean PUFA flux level of subjects followed for a minimum of 5 years that maintained normal cognitive status.
- the present invention also include methods of monitoring the progression of memory impairment or brain injury in a subject, with the methods comprising determining the subject's PUFA influx levels more than once over a period of time.
- some embodiments of the methods of the present invention will comprise determining the subject's PUFA influx levels two, three, four, five, six, seven, eight, nine, 10 or even more times over a period of time, such as a year, two years, three, years, four years, five years, six years, seven years, eight years, nine years or even 10 years or longer.
- the methods of the present invention would also include embodiments in which the subject's influx levels are assessed during and after treatment of memory impairment and/or brain injury.
- the present invention also includes methods of monitoring the efficacy of treatment of memory impairment or monitoring methods of treating brain injury by assessing the subject's influx levels over the course of the treatment and after the treatment.
- the treatment may be any treatment designed to increase a subject's ability to recall past events, i.e., improve a subject's memory, or to alleviate the symptoms of the brain injury.
- normal influx levels are assessed in a sample from a different subject or patient (from the subject being analyzed) and this different subject does not have or is not suspected of having memory impairment or brain injury.
- normal influx levels are assessed in a population of healthy individuals, the constituents of which display no memory impairment or brain injury.
- the subject's influx levels can be compared to normal influx levels generated from a single normal sample or normal influx levels generated from more than one normal subject sample.
- the attending health care provider may subsequently prescribe or institute a treatment program.
- the present invention also provides for methods of screening individuals as candidates for treatment of memory impairment.
- the attending healthcare worker may begin treatment, based on the subject's influx levels, before there are perceivable, noticeable or measurable signs of memory impairment in the individual.
- the invention provides methods of treating memory impairment in a subject in need thereof.
- the treatment methods include obtaining a subject's PUFA or composite profile as defined herein and prescribing a treatment regimen to the subject if the PUFA and/or composite profile indicate that the subject is at risk of suffering from memory impairment.
- the methods of treatment also include methods of monitoring the effectiveness of a treatment for memory impairment.
- a treatment regimen has been established, with or without the use of the methods of the present invention to assist in a diagnosis of memory impairment
- the methods of monitoring a subject's PUFA or composite profile over time can be used to assess the effectiveness of a memory impairment treatment.
- the subject's PUFA or composite profile can be assessed over time, including before, during and after treatments for memory impairment.
- the PUFA or composite profile can be monitored, with, for example, the normalization or decline in the values of the profile over time being indicative that the treatment may showing efficacy or may lead to improvement in the subjects memory and/or cognitive abilities.
- Suitable treatments for memory impairment that may be initiated in response to an indication that the subject is at risk of suffering from memory impairment include but are not limited to prescribing or administering fenofibrate, cholinesterase inhibitors and memantine to the subject.
- cholinesterase inhibitors include but are not limited to donepezil, rivastigmine and galantamine.
- Another treatment includes but is not limited to SOUVENAIDTM, which is a mixture of omega-3 fatty acids, choline, uridine monophosphate and a mixture of antioxidants and B vitamins.
- Other treatments for memory impairment include consumption of coconut oil, ginger, green tea, fatty fish, cold-water fish such as but not limited to salmon, tuna, trout, mackerel and sardines, soy products, blueberries and other dark berries, green leafy vegetables and cruciferous vegetables such as but not limited to broccoli.
- Normative data for Z-score calculations were derived from the performance of the participants on each of the cognitive tests adjusted for age, education, sex, and visit.
- Impairment was defined as a Z-score 1.35 SD below the cohort median. All participants classified as aMCI met recently revised criteria for the amnestic subtype of MCI. Other behavioral phenotypes of MCI were excluded to concentrate on the amnestic form, which most likely represents nascent Alzheimer's pathology. All early AD participants met recently revised criteria for probable Alzheimer's disease with impairment in memory and at least one other cognitive domain.
- Z mem (last), Z att (last), Z exe (last), Z lan (last), and Z vis (last) were defined as the age-gender-education-visit-adjusted robust Z-scores for the last available visit for each subject.
- the aMCI/AD group was defined as those participants whose adjusted Z mem was 1 IQR below the median at their last available visit, i.e., Z mem (last) ⁇ 1.35.
- the neurocognitive analyses were designed to demonstrate the general equivalence of the discovery and validation samples on clinical and cognitive measures.
- Separate Multivariate Analysis of Variance (MANOVA's) tests were used to examine discovery/validation group performance on the composite Z-scores and on self-report measures of memory complaints, memory related functional impairment, depressive symptoms, and a global measure of cognitive function.
- MANOVA Multivariate Analysis of Variance
- LC/MS-grade acetonitrile (ACN), Isopropanol (IPA), water and methanol were purchased from Fisher Scientific (New Jersey, USA). High purity formic acid (99%) was purchased from Thermo-Scientific (Rockford, Ill.).
- Debrisoquine, 4-Nitrobenzoic acid (4-NBA), Pro-Asn, Glycoursodeoxycholic acid, Malic acid were purchased from Sigma (St. Louis, Mo., USA). All lipid standards including 14:0 LPA, 17:0 Ceramide, 12:0 LPC, 18:0 Lyso PI and PC(22:6/0:0) were procured from Avanti Polar Lipids Inc. (USA).
- the plasma samples were thawed on ice and vortexed.
- 25 ⁇ L of plasma sample was mixed with 175 ⁇ l of extraction buffer (25% acetonitrile in 40% methanol and 35% water) containing internal standards [10 ⁇ l of debrisoquine (1 mg/mL), 50 ⁇ L of 4, nitro-benzoic acid (1 mg/mL), 27.3 ⁇ l of Ceramide (1 mg/mL) and 2.5 ⁇ L of LPA (lysophosphatidic acid) (4 mg/mL) in 10 mL).
- the samples were incubated on ice for 10 minutes and centrifuged at 14,000 rpm at 4° C. for 20 minutes.
- the supernatant was transferred to a fresh tube and dried under vacuum.
- the dried samples were reconstituted in 200 ⁇ L of buffer containing 5% methanol, 1% acetonitrile and 94% water.
- the samples were centrifuged at 13,000 rpm for 20 minutes at 4° C. to remove fine particulates.
- the supernatant was transferred to a glass vial for UPLC-ESI-Q-TOF-MS analysis.
- Each sample (2 ⁇ L) was injected onto a reverse-phase CSH C18 1.7 ⁇ M 2.1 ⁇ 100 mm column using an Acquity H-class UPLC system (Waters Corporation, USA).
- the gradient mobile phase comprised of water containing 0.1% formic acid solution (Solvent A), 100% acetonitrile (Solvent B) and 10% acetonitrile in isopropanol (IPA) containing 0.1% formic acid and 10 mM Ammonium formate (Solvent C).
- Each sample was resolved for 13 minutes at a flow rate of 0.5 mL/min for 8 min and then 0.4 mL/min from 8 to 13 min.
- the UPLC gradient consisted of 98% A and 2% B for 0.5 min then a ramp of curve 6 to 60% B and 40% A from 0.5 min to 4.0 min, followed by a ramp of curve 6 to 98% B and 2% A from 4.0 to 8.0 min, then ramped to 5% B and 95% C from 9.0 min to 10.0 min at a flow rate of 0.4 ml/min, and finally to 98% A and 2% B from 11.0 min to 13 minutes.
- the column eluent was introduced directly into the mass spectrometer by electrospray ionization.
- Mass spectrometry was performed on a Quadrupole-Time of Flight (Q-TOF) instrument (Xevo G2 QTOF, Waters Corporation, USA) operating in either negative (ESI ⁇ ) or positive (ESI + ) electrospray ionization mode with a capillary voltage of 3200 V in positive mode and 2800 V in negative mode, and a sampling cone voltage of 30 V in both modes.
- the desolvation gas flow was set to 750 Lh ⁇ 1 and the temperature was set to 350° C. while the source temperature was set at 120° C.
- pooled quality control (QC) samples (generated by taking an equal aliquot of all the samples included in the experiment) were run at the beginning of the sample queue for column conditioning and every ten injections thereafter to assess inconsistencies that are particularly evident in large batch acquisitions in terms of retention time drifts and variation in ion intensity over time.
- This approach has been recommended and used as a standard practice by leading metabolomics researchers.
- a test mix of standard metabolites was run at the beginning and at the end of the run to evaluate instrument performance with respect to sensitivity and mass accuracy.
- the overlay of the total ion chromatograms of the quality control samples depicted excellent retention time reproducibility.
- the sample queue was randomized to remove bias.
- the TICs for each of the three groups showed characteristic patterns.
- Targeted metabolomic analysis of plasma sample was performed using the Biocrates Absolute-IDQ P180 (BIOCRATES, Life Science AG, Innsbruck, Austria). This validated targeted assay allows for simultaneous detection and quantification of metabolites in plasma samples (10 ⁇ L) in a high throughput manner. The methods have been described in detail.
- the plasma samples were processed as per the instructions by the manufacturer and analyzed on a triple quadrupole mass spectrometer (Xevo TQ-S, Waters Corporation, USA) operating in the MRM mode. The measurements were made in a 96 well format for a total of 148 samples, seven calibration standards and three quality control samples were integrated in the kit.
- FIA flow injection analysis tandem mass spectrometry
- MS/MS flow injection analysis tandem mass spectrometry
- the kit facilitated absolute quantitation of 21 amino acids, hexose, carnitine, 39 acylcarnitines, 15 sphingomyelins, 90 phosphatidylcholines and 19 biogenic amines.
- Data analysis was performed using the MetIQ software (Biocrates) while the statistical analyses were performed using the STAT pack module v3 (Biocrates).
- the abundance was calculated from area under the curve by normalizing to the respective isotope labeled internal standard. The concentration is expressed as nmol/L. Quality control samples were used to assess reproducibility of the assay. The mean of the coefficient of variation (CV) for the 180 metabolites was 0.08 and 95% of the metabolites had a CV of ⁇ 0.15.
- the m/z features of metabolites were normalized with log transformation that stabilized the variance followed with a quantile normalization to make the empirical distribution of intensities the same across samples.
- the metabolites were selected among all those known to be identifiable using a ROC regularized learning technique, based on the least absolute shrinkage and selection operator (LASSO) penalty as implemented with the R package ‘glmnet’, which uses cyclical coordinate descent in a pathwise fashion.
- the regularization path over a grid of values was obtained for the tuning parameter lambda through 10-fold cross-validation.
- the optimal value of the tuning parameter lambda which was obtained by the cross-validation procedure, was then used to fit the model. All the features with non-zero coefficients were retained for subsequent analysis.
- the classification performance of the selected metabolites was assessed using area under the ROC (receiver operating characteristic) curve (AUC).
- AUC receiver operating characteristic
- the ROC can be understood as a plot of the probability of classifying correctly the positive samples against the rate of incorrectly classifying true negative samples.
- the AUC measure of an ROC plot is actually a measure of predictive accuracy.
- the simple logistic model with the ten metabolite panel was used, although a more refined model can yield greater AUC.
- the aMCI/AD, Converter, and NC groups were defined primarily using a composite measure of memory performance in addition to composite measures of other cognitive abilities and clinical measures of memory complaints and functional capacities. (See Tables 1 and 2).
- GDS-SF Geriatric Depression Scale-Short Form
- WMS-III FDS Wechsler Memory Scale- III Manual. San Antonio, TX: The Psychological Corporation, 1997. Trail Making Test- Part A (TMT-A) Completion Attention Reitan R M. (1958).
- HVOT Hooper Visual Organization Test
- the plasma samples from the 124 discovery phase participants were subjected to lipidomics analysis.
- metabolomic/lipidomic profiling yielded 2700 features in the positive mode and 1900 features in the negative mode.
- the metabolites that define the participant groups were selected from among all known to be identifiable using a regularized learning technique, the least absolute shrinkage and selection operator (LASSO) penalty as implemented with the R package ‘glmnet’.
- the LASSO analysis revealed features that assisted in unambiguous class separation between a MCI/AD, Converter pre and the NC group (Table 4).
- the markers in Table 1 were chosen based on the significant predictive value as determined by LASSO coefficient analysis.
- the positive estimated LASSO coefficient suggests elevation in corresponding comparison group (a MCI/AD and Converter pre ) compared to normal control (NC) participants.
- Up arrows indicate up-regulation in the comparison group as compared to the NC participants while the down arrow suggests down-regulation in these groups.
- This untargeted lipidomic analysis revealed a significant decrease in the level of phosphatidyl inositol (PI) in the Converter pre group and an elevation in the plasma levels of glycoursodeoxycholic acid in the a MCI/AD patients as compared to the NC group.
- PI phosphatidyl inositol
- These metabolites were unambiguously identified using tandem mass spectrometry.
- the other metabolites that displayed differential abundance in the study groups consisted of amino acids, biogenic amines and a broad range of phospholipids and other lipid species that were putative identified based on accurate mass stringency of ⁇ 5 ppm.
- MRM multiple reaction monitoring
- SID-MS stable isotope dilution-mass spectrometry
- Up arrows in Table 5 indicate up-regulation in the comparison group as compared to the normal control (NC) participants while the down arrow suggests down-regulation in these groups.
- the targeted metabolomic/lipidomic analysis identified of a set of ten metabolites, comprised of PCs, lyso PCs, and ACs that were depleted in the plasma of the Converter pre participants compared to the NC group. These metabolites remain depleted after the same participants phenoconverted to aMCI/AD (Converters post ) and were nearly equivalent to the low levels seen in the cognitively impaired a MCI/AD group.
- a simple logistic model with the ten metabolite panel was used to predict/classify Converter pre and NC participants. When displayed as a ROC curve, the ten metabolite panel comparing Converter pre and NC participants yielded an AUC of 0.96, while the panel yielded an AUC of 0.827 for the aMCI/AD vs NC classification.
- the validation analysis revealed lower levels of the assayed metabolites in groups A and B compared to group C. Based on these qualitative differences, it was predicted that group C was the NC group and groups A and B were Converter pre and aMCI/AD groups, respectively. Subsequent un-blinding of the groups confirmed these predictions.
- the metabolomic data was used from the untargeted LASSO analysis to build separate linear classifier models that would distinguish the aMCI/AD group from the NC group and the Converter pre group from the NC group.
- a receiver operating characteristic (ROC) analysis was employed to determine the area under the ROC curve (AUC) to assess the performance of the classifier models in differentiating the groups.
- ROC receiver operating characteristic
- AUC area under the ROC curve
- APOE apolipoprotein E genotype
- ApoE protein is involved in lipid transport/metabolism and APOE allele status, including homozygous ( ⁇ 2/2 vs. ⁇ 3/3 vs. ⁇ 4/4) and heterozygous ( ⁇ 2/3 vs. ⁇ 2/4 vs. ⁇ 3/4) options, alter the risk for Alzheimer's Disease (AD).
- AD Alzheimer's Disease
- Alzheimer's disease is a cognitive disorder defined in numerous diagnostic schemes by a primary impairment in memory.
- the classification of preclinical Alzheimer's disease via PADI relies heavily on the assessment of memory, but it is recognized that the preclinical state may also involve other cognitive domains, thus the methods disclosed herein rely on assessing all primary cognitive domains (Table 6).
- the primary Memory outcome was based on the Rey Auditory Visual Learning Test (RAVLT). Learning was defined as the sum of the number of correct words recalled over the 5 learning trials; Retrieval was defined as the total number of correct words recalled from trial A7; and Retention was defined as the total number correct words recognized minus the number of false positives.
- RAVLT Rey Auditory Visual Learning Test
- Each of these three sub-scores was converted to an empirical Z-score by subtracting its sample mean and dividing by its sample SD.
- the three resulting positively correlated RAVLT-based Z-scores were then averaged to form the composite Memory score (Zmem). So defined, Zmem was approximately normal with mean 0, SD ⁇ 1, and some negative skewness attributable to the fact that healthy participants often score at or near the upper bounds, especially for Retention.
- the Attention (Zatt), Executive (Zexe), and Language (Zlan) scores were each defined as averages of empirical Z-score transforms of pairs of subscores, as follows.
- Zatt (1) completion time (in seconds, truncated at 300 s) for the Trail Making Test Part A and (2) the Wechsler Memory Scale-Ill Forward Digit Span; Zexe: (1) completion time (in seconds, truncated at 300 s) for the Trail Making Test Part B and (2) the Wechsler Memory Scale-Ill Backward Digit Span; Zlan: (1) total score (out of 60) for the Boston Naming Test and (2) Category Fluency (Animals Named in 1 minute).
- the Visuoperceptual score (Zvis) was simply the empirical Z-transform of the Total Score (out of 30) for the Hooper Visual Organization Test (HVOT), which itself was approximately normally distributed. See Table 2 for composite Z score components.
- Memory increased with years of education between 5-12 years, decreased between 12-14 years, increased again between 14-16 years, and then nearly leveled off for 16-23 years.
- Age was modeled linearly, as there was insufficient evidence to support nonlinearity via piecewise linear spline knots or a quadratic component, yet Memory scores decreased linearly with age.
- Visit was modeled via an indicator for baseline visit 0, given that there was insufficient evidence that subsequent visits differed from each other, yet there was evidence that subsequent visits had higher Memory scores compared with baseline visit 0.
- Gender was modeled via an indicator for males, who had lower memory scores than females. There was insufficient evidence to support any interactions.
- the choice to use robust measures of location (median) and dispersion (IQR) was made to reduce the influence that cognitively impaired participants might have on the mean and SD, and in recognition of the slight negative skewness of the residuals.
- the robustly standardized residuals were then viewed as age-gender-education-visit-adjusted robust Z-scores for each of the five cognitive domains.
- Zmem(last), Zatt(last), Zexe(last), Zlan(last), and Zvis(last) were defined as the age-gender-education-visit-adjusted robust Z-scores for the last available visit for each subject.
- the aMCI/AD group was defined as those participants whose adjusted Zmem was 1 IQR below the median at their last available visit, i.e., Zmem(last) ⁇ 1.35.
- NC participants were frequency matched to the aMCI/AD participants for each of the Discovery and Validation samples based on age, education, and sex. This was accomplished by stratifying the sample by four groups of age at the last visit (75-79, 80-85, 86-94, 95-100), three education groups (5-12, 13-18, 19-23), and two sexes (male, female), resulting in 24 age-education-sex strata.
- the PADI was constructed by combining the two domains (weighted ⁇ 0.484 for attention and ⁇ 0.516 for memory) such that higher scores indicate poorer cognitive performance.
- HVOT Hooper Visual Organization Test
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
- Part of the work performed during development of this invention utilized U.S. Government funds under National Instituted of Health Grant No. R01 AG030753 and Department of Defense Contract No. W81XWH-09-1-0107. The U.S. Government has certain rights in this invention.
- The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise determining the influx of polyunsaturated fatty acids (PUFAs) into the brain from plasma in a test subject and comparing this measured influx to a normal standard influx. An increase in influx of PUFAs from the plasma into the brain is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.
- Alzheimer's disease (AD) is a neurodegenerative disorder characterized by a progressive dementia that insidiously and inexorably robs older adults of their memory and other cognitive abilities. The prevalence of AD is expected to double every 20 years from 35.6 million individuals worldwide in 2010 to 115 million affected individuals by 2050. There is no cure and current therapies are unable to slow the disease progression.
- Early detection of the at-risk population (preclinical), or those in the initial symptomatic stages (prodromal) of AD, may present opportunities for more successful therapeutic intervention, or even disease prevention by interdicting the neuropathological cascade that is characterized by the deposition of extracellular β-amyloid (Aβ) and accumulation of intracellular fibrils of microtubular hyperphosphorylated tau protein within the brain. Biomarkers for early disease, including cerebrospinal fluid (CSF) tau and Aβ levels, structural and functional magnetic resonance imaging (MRI), and the recent use of brain amyloid imaging, are of limited use for widespread screening since they provide diagnostic options that are either invasive, i.e., require lumbar puncture, time-consuming, i.e., several hours in a scanner for most comprehensive imaging protocols, or expensive. No current blood-based biomarkers can detect incipient dementia with the required sensitivity and specificity at a preclinical stage. Continued interest in blood-based biomarkers remains because these specimens are obtained using rapid, minimally invasive methods. With recent technological advances in ‘omics’ and systems level approaches, the comprehensive bioinformatic analyses of prognostic biomarkers may yield new insights into the underlying mechanisms and pathobiological networks of AD and possibly herald the development of new therapeutic strategies.
- The preclinical interval resulting in mild cognitive impairment (MCI) or AD is known to be variable, multifactorial, and extends up to 7-10 years prior to the emergence of clinical signs. In the absence of valid and reliable biomarkers, multimodal neurocognitive testing remains the most accurate, standardized, and widely used pre-mortem screening method to determine clinical MCI or AD. The utility of strict cognitive assessment for preclinical states of MCI or AD is limited, however, as this approach is time-consuming and expected to be present almost all individuals as normal, as it quantitatively delineates specific brain properties, such as language, thought, and behavior, which is typically not affected in individual in the preclinical state. Thus, what is needed is a diagnostic method that is quick, effective, less invasive and accurate in determining future onset of MCI and/or AD.
- The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise determining the influx of polyunsaturated fatty acids (PUFAs) into the brain from plasma in a test subject and comparing this measured influx to a normal standard influx. An increase in influx of PUFAs from the plasma into the brain is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.
-
FIG. 1 depicts a schematic representation of potential alterations within brain and peripheral blood responsible for reduced plasma phospholipid levels. 1A shows a theoretical qualitative dot plot of differential changes occurring in cognitively normal control (NC), cognitively normal Converterpre (Cpre) subjects, and those with amnestic mild cognitive impairment or Alzheimer's disease (a MCI/AD). Note that all four processes are at the zero relative level in the NC subjects. Going from left to right, the first dot is the levels of PUFA influx into the brain; the second dot is levels of plasma PUFAs, the third dot is level of active neuroinflammation and the last dot on the right is the degree of brain injury. The Cpre subjects show significant transport of polyunsaturated fatty acid (PUFA) into the brain, likely to replenish lost substrate from inflammation, oxidative stress or other brain injury or metabolic abnormality. The increase in PUFA flux into the brain is an attempt to compensate for ongoing injury and results in a marked reduction in the plasma levels of molecules carrying those lipid species. 1B. shows qualitative depiction of plasma phospholipid biomarker results previously quantified and specified (Mapstone et al., 2014, Fiandaca, et al., Alzheimer's & Dementia 10 (2014) S196-S212). Dark horizontal line within boxes represents proposed mean levels of metabolites for the group. -
FIG. 2 depicts the performance of the Preclinical Alzheimer's Disease Index (PADI).FIG. 2A depicts the results of the ROC analysis of baseline PADI on phenoconversion to MCI/AD (AUC=0.93);FIG. 2B depicts the survival analysis of baseline PADI on accumulative MCI/AD cases over 5 years adjusting for age, years of education, APOE4 carrier, global cognition, depression, and memory complaints. - The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise determining the influx of polyunsaturated fatty acids (PUFAs) into the brain from plasma in a test subject and comparing this measured influx to a normal standard influx. An increase in influx of PUFAs from the plasma into the brain is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.
- As used herein, the term subject or “test subject” indicates a mammal, in particular a human or non-human primate. The test subject may or may not be in need of an assessment of a predisposition to memory impairment. For example, the test subject may have a condition or may have been exposed to injuries or conditions that are associated with memory impairment prior to applying the methods of the present invention. In another embodiment, the test subject has not been identified as a subject that may have a condition or may have been exposed to injuries or conditions that are associated with memory impairment prior to applying the methods of the present invention.
- As used herein, the phrase “memory impairment” means a measureable or perceivable decline or decrease in the subject's ability to recall past events. As used herein, the term “past events” includes both recent (new) events (short-term memory) or events further back in time (long-term memory). In one embodiment, the methods are used to assess an increased risk for short-term memory impairment. In another embodiment, the methods are used to assess an increased risk for long-term memory impairment. The measureable or perceivable decline in the subject's ability to recall past events may be assessed clinically by a health care provider, such as a physician, physician's assistant, nurse, nurse practitioner, psychologist, psychiatrist, hospice provider, or any other provider that can assess a subject's memory. The measureable or perceivable decline in the subject's ability to recall past events may be assessed in a less formal, non-clinical manner, including but not limited to the subject himself or herself, acquaintances of the subject, employers of the subject and the like. The invention is not limited to a specific manner in which the subject's ability to recall a past event is assessed. In fact, the methods of the invention can be implemented without the need to assess a subject's ability to recall past events. Of course, the methods of the present invention may also include assessing the subject's ability to assess past events one or more times, both before determining the subject's influx levels and after determining the subject's influx levels at least one time.
- In one embodiment, the methods may also comprise assessing the individual's Preclinical Alzheimer's Disease Index (PADI). As used herein, PADI is an assessment of an individual's likelihood of developing memory impairment based on a novel, synthetic scoring valuation comprising a memory component and an attention component. In one embodiment, the PADI of the individual is assessed prior to determining the subject's PUFA profile and the PUFA profile is then used to further stratify subjects that are considered at risk of suffering from memory impairment based on the PADI. In another embodiment, the PADI of the individual is assessed after determining the subject's PUFA profile and the PADI is then used to further stratify subjects that are considered at risk of suffering from memory impairment based on the PUFA profile. In yet another embodiment, the PADI profile and the PUFA profile are assessed in conjunction with one another such that the combined composite profile is determined prior to any initial patient population stratification.
- In one embodiment, the PADI is calculated as a simple ratio between attention performance evaluations and memory performance evaluations. In one embodiment, the PADI is calculated as a weighted ratio between attention performance evaluations and memory performance evaluations. In specific embodiments, the attention component is weighted less than the memory component in calculating the PADI, i.e., the value of the attention is component less than 1:1, i.e., between about 0.001 and about 0.499. In more specific embodiments, the attention component is weighted between about 0.499 about 0.200, between about 0.490 and about 0.300 and between about 0.485 and about 0.400. Conversely, in some embodiments, the memory component is weighted more than the attention component in calculating the PADI, i.e., the value of the attention component is more than 1:1, i.e., between about 0.501 and about 0.999. For example, in more specific embodiments, the memory component is weighted between about 0.501 and 0.800, between about 0.510 and about 0.700 and between about 0.515 and about 0.600. Of course, the signs of relative weights in determining the ratios could be reversed for each component, e.g., the weight of the attention component could be between −0.001 and −0.500 and the weight of the memory component could be between about −0.0500 and −0.999 such that the “higher” PADI score indicates that the subject has a higher risk of suffering from memory impairment.
- As used herein, the phrase “PUFA profile” (or “metabolite profile”) means the combination of a subject's PUFAs found in the peripheral blood or portions thereof, such as but not limited to plasma or serum. The PUFA profile is a collection of measurements, such as but not limited to a quantity or concentration, for individual metabolites taken from a test sample of the subject. Examples of test samples or sources of components for the PUFA profile include, but are not limited to, biological fluids, which can be tested by the methods of the present invention described herein, and include but are not limited to whole blood, such as but not limited to peripheral blood, serum, plasma, cerebrospinal fluid, urine, amniotic fluid, lymph fluids, and various external secretions of the respiratory, intestinal and genitourinary tracts, tears, saliva, milk, white blood cells, myelomas and the like. Test samples to be assayed also include but are not limited to tissue specimens including normal and abnormal tissue.
- In specific embodiments, the subject's PUFA profile is combined with the subject's PADI to provide a composite score for assessing the risk that the subject will suffer from future memory impairment. Accordingly, select embodiments of the methods of the present invention comprise obtaining a PUFA profile, obtaining a PADI and combining each of the profiles to obtain a composite profile having a performance component and a biological component.
- In one embodiment, the composite profile is calculated as a simple ratio between the PADI and the PUFA profile. In one embodiment, the composite profile is calculated as a weighted ratio between the PADI and the PUFA profile. In specific embodiments, the PADI component is weighted less than the PUFA component in calculating the composite profile, i.e., the value of the PADI component is less than 1:1, i.e., between about 0.001 and about 0.499. In more specific embodiments, the PADI component is weighted between about 0.499 about 0.200, between about 0.490 and about 0.300 and between about 0.485 and about 0.400. In additional embodiments, the PADI component is weighted more than the PUFA component in calculating the composite profile, i.e., the value of the PADI component is more than 1:1, i.e., between about 0.501 and about 0.999. For example, in more specific embodiments, the PADI component is weighted between about 0.501 and 0.800, between about 0.510 and about 0.700 and between about 0.515 and about 0.600. Conversely, in some embodiments, the PUFA component is weighted more than the PADI component in calculating the composite, i.e., the value of the PADI component is more than 1:1, i.e., between about 0.501 and about 0.999. For example, in more specific embodiments, the PUFA component is weighted between about 0.501 and 0.800, between about 0.510 and about 0.700 and between about 0.515 and about 0.600. In additional embodiments, the PUFA component is weighted less than the PADI component in calculating the composite profile, i.e., the value of the PUFA component is less than 1:1, i.e., between about 0.001 and about 0.499. In more specific embodiments, the PUFA component is weighted between about 0.499 about 0.200, between about 0.490 and about 0.300 and between about 0.485 and about 0.400. Of course, the signs of relative weights in determining the composite could be reversed for each component, e.g., the weight of the PADI component could be between −0.001 and −0.500 and the weight of the PUFA component could be between about −0.0500 and −0.999 such that the “higher” composite profile indicates that the subject has a higher risk of suffering from memory impairment.
- In one embodiment, the decline or decrease in the ability to recall past events is relative to each individual's ability to recall past events prior to the diagnosed decrease or decline in the ability to recall past events. In another embodiment, the decline or decrease in the ability to recall past events is relative to a population's (general, specific or stratified) ability to recall past events prior to the diagnosed decrease or decline in the ability to recall past events.
- As used herein, the term means “increased risk” is used to mean that the test subject has an increased chance of developing or acquiring memory impairment compared to a normal individual. The increased risk may be relative or absolute and may be expressed qualitatively or quantitatively. For example, an increased risk may be expressed as simply determining the subject's PUFA flux levels and placing the patient in an “increased risk” category, based upon previous PUFA flux population studies. Alternatively, a numerical expression of the subject's increased risk may be determined based upon the measured PUFA flux levels. As used herein, examples of other expressions of an increased risk include but are not limited to, odds, probability, odds ratio, p-values, attributable risk, relative frequency, positive predictive value, negative predictive value, and relative risk.
- While the brain has the capacity to generate all of the lipid species it requires for normal function, in addition to most saturated and mono-unsaturated fatty acids, the substrates required for such independent maintenance of brain lipid homeostasis, especially sources of energy and PUFAs, are delivered via the bloodstream. In normal brain processing, lipid precursor components are recycled and have relatively long half-lives, especially certain fatty acid components of phospholipids (Edmond, 2001). Some PUFAs, such as docosahaxaenoic acid (DHA; 22:6 n-3) and arachidonic acid (AA; 20:4 n-6) provide structural functionality as phospholipid components in bilayer membranes and, once released, either directly or through byproducts, participate in signal transduction processes with both positive and negative consequences within cells. In cases where brain membrane lipids undergo catabolism, e.g., cases of oxidative stress, or neuroinflammation, the downstream intermediates often are not recycled, thereby increasing demand for lipid precursors from the bloodstream. Such precursors exist in plasma as unesterified fatty acids (FAs) 22 carbons) bound to albumin, or as esterified FA components (>22 carbons) incorporated into circulating phospholipid species preferentially transported within lipoproteins. Triacylglycerols, diacylglycerophospholipids and lysophosphoglycerophospholipids represent major circulating esterified forms. Certain lysophosphatidylcholine species appear to be more efficiently transported into the brain from plasma compared to triacylglycerol or unesterified fatty acids (Lagarde et al., 2001). Esterified FAs are typically converted to unesterified forms by lipases within the lipoproteins or within the blood, prior to their passage (or flux) into the brain. Flux of unesterified FAs into the brain, across the blood-brain barrier (BBB), occurs via simple diffusion and possibly via facilitated transport. All unesterified FAs entering the brain are immediately esterified by acetyl-CoA-synthase, preventing their diffusion back to blood and preparing them for incorporation into lipid synthetic pathways or for β-oxidation. Activation of phospholipases, e.g., PLA2, with increased oxidative stress, is implicated in diminishing PUFAs from PCs and other lipid species within cellular membranes. Esterified FAs are converted to unesterified forms by lipases within the lipoproteins or within the blood, prior to their passage (or flux) into the brain. Flux of unesterified FAs into the brain, across the blood-brain barrier (BBB), occurs via simple diffusion and possibly via facilitated transport. All unesterified FAs entering the brain are immediately esterified by acetyl-CoA-synthase, preventing their diffusion back to blood and preparing them for incorporation into lipid synthetic pathways or for β-oxidation. Activation of phospholipases, e.g., PLA2, with increased oxidative stress, is implicated in diminishing PUFAs from PCs and other lipid species within cellular membranes.
- Thus measuring plasma fatty acids, in particular, measuring their flux into the central nervous system, provides a key indicator of ongoing abnormal lipid metabolism in the brain, which, in turn, can signify an active process of brain injury and/or pending development of memory loss. In one embodiment, the fatty acids are polyunsaturated fatty acids (PUFAs). In a more specific embodiment, the PUFAs used in the methods of the present invention are omega-3 fatty acids and/or omega-6 fatty acids. In another specific embodiment, the PUFAs for which influx is measured are essential fatty acids.
- Omega-3 PUFAs include but are not limited to Hexadecatrienoic acid (HTA), Alpha-linolenic acid (ALA), Stearidonic acid (SDA), Eicosatrienoic acid (ETE), Eicosatetraenoic acid (ETA), Eicosapentaenoic acid (EPA), Heneicosapentaenoic acid (HPA), Docosapentaenoic acid (DPA) Docosahexaenoic acid (DHA), Tetracosapentaenoic acid and Tetracosahexaenoic acid (Nisinic acid). In certain embodiment, the influx of any one or more of the omega-3 fatty acids listed herein can be used in any of the methods of the present invention.
- Omega-6 PUFAs include but are not limited to Linoleic acid (LA), Gamma-linolenic acid (GLA), Eicosadienoic acid, Dihomo-gamma-linolenic acid (DGLA), Arachidonic acid (AA), Docosadienoic acid, Adrenic acid, Docosapentaenoic acid (Osbond acid), Tetracosatetraenoic acid and Tetracosapentaenoic acid. In certain embodiment, the influx of any one or more of the omega-6 fatty acids listed herein can be used in any of the methods of the present invention.
- In one embodiment, the PUFAs used in the methods of the present invention are the essential fatty acids alpha linolenic acid (ALA) or linoleic acid (LA). In another embodiment, both ALA and LA are used in the methods of the present invention.
- In another embodiment, the PUFAs used in the methods of the present invention are EPA, DHA and/or AA. In another embodiment, EPA and DHA are used in the methods of the present invention. In another embodiment, AA and DHA are used in the methods of the present invention. In another embodiment, EPA and AA are used in the methods of the present invention. In another embodiment, AA, EPA and DHA are used in the methods of the present invention.
- To measure influx of the PUFAs used in the methods of the present invention, the PUFAs can be labeled and then administered to the subject. Current methods and equipment can then be used to trace and monitor the movement of the labeled PUFAs from the circulation into the brain (“influx”) of the subject. As used herein, the term “influx” refers to the movement of a molecule, such as a labeled PUFA, into the brain and across the blood brain barrier of a subject, such that the labeled PUFA would no longer be considered as being in the general circulation. Routes of administration of the labeled PUFAs are well known and include oral, nasal, intravenous injection, intramuscular injection, intraperitoneal injection and the like. The methods of the present invention are not limited to the routes of administration of the labeled PUFA.
- In select embodiments, the PUFAs used in the methods of the present invention are labeled using a radioactive isotope. For example, the Carbon-11 (11C) isotope can be used to label the PUFAs to be measured, by incorporating 11C into any of the PUFA carbon atoms. Ideally, the carboxyl carbon (Δ 1) or adjacent carbon (Δ 2) would be tagged and allow that specific molecule to be monitored via positron emission tomography (PET) scanning as it migrates from blood to brain. The chemical tagging of PUFAs with 11C is a known method for physiological monitoring and along with PET scanning to allow determination of flux of 11C-tagged substances into the brain.
- Once administered the labeled PUFAs can be monitored using equipment designed to detect and trace the label. For example, if the PUFAs are labeled using Carbon-11, which decay via positron emission, the influx of the labeled PUFAs can be measured using well-known positron emission tomography (PET) techniques. In another example, if the PUFAs are labeled with a fluorescent dye, e.g., BODIPY™ (4,4-difluoro-3a,4adiaza-s-indacene), the influx of the labeled PUFAs can be measured using in vivo fluorescent microscopy.
- The correlation between a subject's measured PUFA flux value and the likelihood of suffering from memory impairment may be measured by an odds ratio (OR) and by the relative risk (RR). If P(R+) is the probability of developing memory impairment for individuals with the determined influx levels (R) and P(R−) is the probability of developing memory impairment for individuals having normal influx levels, then the relative risk is the ratio of the two probabilities: RR=P(R+/P(R−).
- In case-control studies, however, direct measures of the relative risk often cannot be obtained because of sampling design. The odds ratio allows for an approximation of the relative risk for low-incidence diseases and can be calculated: OR=(F+/(1−F+))/(F−/(1−F−)), where F+ is the frequency of measured influx levels in cases studies and F− is the frequency of measured influx levels in controls. F+ and F− can be calculated using the measured d influx level frequencies of the study.
- The attributable risk (AR) can also be used to express an increased risk. The AR describes the proportion of individuals in a population exhibiting memory impairment due to a certain minimum or maximum influx level. The public health relevance of the AR measurement lies in estimating the proportion of cases of memory impairment in the population that could be prevented if the influx levels were not abnormal. AR may be determined as follows: AR=PE(RR−1)/(PE(RR−1)+1), where AR is the risk attributable to a minimum (or maximum) measured influx, and PE is the frequency of certain influx level within the population at large. RR is the relative risk, which can be approximated with the odds ratio when the influx levels under study have a relatively low incidence in the general population.
- In one embodiment, the increased risk of a patient can be determined from p-values that are derived from association studies. Specifically, associations with specific PUFA flux levels can be performed using regression analysis by regressing the PUFA flux levels with memory impairment. In addition, the regression may or may not be corrected or adjusted for one or more factors. The factors for which the analyses may be adjusted include, but are not limited to age, sex, weight, ethnicity, geographic location, fasting state, state of pregnancy or post-pregnancy, menstrual cycle, general health of the subject, alcohol or drug consumption, caffeine or nicotine intake and circadian rhythms, and the subject's apolipoprotein epsilon (ApoE) genotype to name a few.
- Increased risk can also be determined from p-values that are derived using logistic regression. Binomial (or binary) logistic regression is a form of regression that is used when the dependent is a dichotomy and the independents are of any type. Logistic regression can be used to predict a dependent variable on the basis of continuous and/or categorical independents and to determine the percent of variance in the dependent variable explained by the independents; to rank the relative importance of independents; to assess interaction effects; and to understand the impact of covariate control variables. Logistic regression applies maximum likelihood estimation after transforming the dependent into a “logit” variable (the natural log of the odds of the dependent occurring or not). In this way, logistic regression estimates the probability of a certain event occurring. These analyses are conducted with the program SAS.
- SAS (“statistical analysis software”) is a general purpose package (similar to Stata and SPSS) created by Jim Goodnight and N.C. State University colleagues. Ready-to-use procedures handle a wide range of statistical analyses, including but not limited to, analysis of variance, regression, categorical data analysis, multivariate analysis, survival analysis, psychometric analysis, cluster analysis, and nonparametric analysis.
- Accordingly, select embodiments of the present invention comprise the use of a computer comprising a processor and the computer is configured or programmed to generate one or more PUFA profiles and/or to determine statistical risk. The methods may also comprise displaying the one or more profiles and/or risk profiles on a screen that is communicatively connected to the computer. In another embodiment, two different computers can be used: one computer configured or programmed to generate one or more PUFA profiles and a second computer configured or programmed to determine statistical risk. Each of these separate computers can be communicatively linked to its own display or to the same display.
- The assessment for flux of the one or more PUFAs can be expressed as absolute or relative values and may or may not be expressed in relation to another component, a standard an internal standard or another molecule of compound known to be in the sample. If flux is assessed as relative to a standard or internal standard, the standard may be added to the test sample prior to, during or after sample processing.
- The subject's flux measurement(s) is(are) compared to flux measurements deemed to be normal. To establish influx in a normal individual, an individual or group of individuals may be first assessed for their ability to recall past events to establish that the individual or group of individuals has a normal or acceptable ability memory. Such individuals would be followed serially in a longitudinal study that documents their lack of development of memory disturbances over at least a 5-year period. Such stable cognitive status and the correlated PUFA flux levels taken serially over this time in the individual or group of individuals would establish a “normal PUFA flux level.” In one embodiment, normal flux levels can be ascertained from the same subject when the subject is deemed to possess normal cognitive abilities and no signs (clinical or otherwise) of memory impairment. In one embodiment, normal flux levels are assessed in the same subject from whom the sample is taken prior to the onset of measureable, perceivable or diagnosed memory impairment. That is, the term “normal” with respect to PUFA flux can be used to mean the subject's baseline PUFA flux prior to the onset of memory impairment. The PUFA flux levels can then be reassessed serially and compared to either the subject's baseline PUFA flux level, or to the mean PUFA flux level of subjects followed for a minimum of 5 years that maintained normal cognitive status.
- Thus, the present invention also include methods of monitoring the progression of memory impairment or brain injury in a subject, with the methods comprising determining the subject's PUFA influx levels more than once over a period of time. For example, some embodiments of the methods of the present invention will comprise determining the subject's PUFA influx levels two, three, four, five, six, seven, eight, nine, 10 or even more times over a period of time, such as a year, two years, three, years, four years, five years, six years, seven years, eight years, nine years or even 10 years or longer.
- The methods of the present invention would also include embodiments in which the subject's influx levels are assessed during and after treatment of memory impairment and/or brain injury. In other words, the present invention also includes methods of monitoring the efficacy of treatment of memory impairment or monitoring methods of treating brain injury by assessing the subject's influx levels over the course of the treatment and after the treatment. The treatment may be any treatment designed to increase a subject's ability to recall past events, i.e., improve a subject's memory, or to alleviate the symptoms of the brain injury.
- In another embodiment, normal influx levels are assessed in a sample from a different subject or patient (from the subject being analyzed) and this different subject does not have or is not suspected of having memory impairment or brain injury. In still another embodiment, normal influx levels are assessed in a population of healthy individuals, the constituents of which display no memory impairment or brain injury. Thus, the subject's influx levels can be compared to normal influx levels generated from a single normal sample or normal influx levels generated from more than one normal subject sample.
- If it is determined that a subject has an increased risk of memory impairment, the attending health care provider may subsequently prescribe or institute a treatment program. In this manner, the present invention also provides for methods of screening individuals as candidates for treatment of memory impairment. The attending healthcare worker may begin treatment, based on the subject's influx levels, before there are perceivable, noticeable or measurable signs of memory impairment in the individual.
- Similarly, the invention provides methods of treating memory impairment in a subject in need thereof. The treatment methods include obtaining a subject's PUFA or composite profile as defined herein and prescribing a treatment regimen to the subject if the PUFA and/or composite profile indicate that the subject is at risk of suffering from memory impairment.
- The methods of treatment also include methods of monitoring the effectiveness of a treatment for memory impairment. Once a treatment regimen has been established, with or without the use of the methods of the present invention to assist in a diagnosis of memory impairment, the methods of monitoring a subject's PUFA or composite profile over time can be used to assess the effectiveness of a memory impairment treatment. Specifically, the subject's PUFA or composite profile can be assessed over time, including before, during and after treatments for memory impairment. The PUFA or composite profile can be monitored, with, for example, the normalization or decline in the values of the profile over time being indicative that the treatment may showing efficacy or may lead to improvement in the subjects memory and/or cognitive abilities.
- Suitable treatments for memory impairment that may be initiated in response to an indication that the subject is at risk of suffering from memory impairment include but are not limited to prescribing or administering fenofibrate, cholinesterase inhibitors and memantine to the subject. Specific examples of cholinesterase inhibitors include but are not limited to donepezil, rivastigmine and galantamine. Another treatment includes but is not limited to SOUVENAID™, which is a mixture of omega-3 fatty acids, choline, uridine monophosphate and a mixture of antioxidants and B vitamins. Other treatments for memory impairment that can be used in conjunction with the present invention include consumption of coconut oil, ginger, green tea, fatty fish, cold-water fish such as but not limited to salmon, tuna, trout, mackerel and sardines, soy products, blueberries and other dark berries, green leafy vegetables and cruciferous vegetables such as but not limited to broccoli.
- All patents and publications mentioned in this specification are indicative of the level of those skilled in the art to which the invention pertains. All patents and publications cited herein are incorporated by reference to the same extent as if each individual publication was specifically and individually indicated as having been incorporated by reference in its entirety
- Neurocognitive Methods
- A total of 525 volunteers participated in this study as part of the Rochester/Orange County Aging Study (R/OCAS), an ongoing natural history study of cognition in community-dwelling older adults. Briefly, participants were followed with yearly cognitive assessments and blood samples were collected following an overnight fast and withholding of all medications. At baseline and each yearly visit, participants completed assessments in such as activities in daily living, memory complaints, signs and symptoms of depression, and were administered a detailed cognitive assessment.
- For this study, data from the cognitive tests were used to classify participants into groups for biomarker discovery. Standardized scores (Z-scores) were derived for each participant on each cognitive test and the composite Z-scores were computed for five cognitive domains (attention, executive, language, memory, visuoperceptual) (Table).
-
TABLE 1 Attention (Zatt) Executive (Zexe) Language (Zlan) Visuoperceptual (Zvis) Memory (Zmem) Wechsler Wechsler 1-min Category Hooper Visual Rey Auditory Memory Scale-III Memory Scale-III fluency Organization Test Verbal Learning Forward Digit Backward Digit (Animals) (HVOT) Test Learning Span Span (RAVLT Learning) (WMS-III FDS) (WMS-III BDS) Trail Making Trail Making Boston Naming Rey Auditory Test- Part A Test- Part B Test 60-Item Verbal Learning (TMT-A) (TMT-B) version (BNT-60) Test Retrieval (RAVLT Retrieval) Rey Auditory Verbal Learning Test Retention (RAVLT Recognition) - Normative data for Z-score calculations were derived from the performance of the participants on each of the cognitive tests adjusted for age, education, sex, and visit. To reduce the effect of cognitively impaired participants on the mean and SD, age-, education-, sex, and visit-adjusted residuals from each domain Z-score model were robustly standardized to have median 0 and robust SD=1, where the robust SD=IQR/1.35, as 1.35 is the IQR (Inter-Quartile Range) of a standard normal distribution.
- The participants were then categorized into groups of incident aMCI or early AD (combined into one category aMCI/AD), cognitively normal control (NC), and those who converted to MCI or AD over the course of the study (Converters) based on these composite scores. Impairment was defined as a Z-score 1.35 SD below the cohort median. All participants classified as aMCI met recently revised criteria for the amnestic subtype of MCI. Other behavioral phenotypes of MCI were excluded to concentrate on the amnestic form, which most likely represents nascent Alzheimer's pathology. All early AD participants met recently revised criteria for probable Alzheimer's disease with impairment in memory and at least one other cognitive domain. For the MCI and early AD groups, scores on the measures of memory complaints (MMQ) and activities of daily living (PGC-IADL) were used to corroborate research definitions of these states. All Converters had non-impaired memory at entry to the study (Zmem≥−1.35), developed memory impairment over the course of the study (Zmem≤−1.35) and met criteria for the above definitions of a MCI or AD. To enhance the specificity of the biomarker analyses, NC participants in this study were conservatively defined with Zmem±1 SD of the cohort median rather than simply ≥−1.35, and all other Z-scores ≥−1.35 SD.
- For each subject, Zmem(last), Zatt(last), Zexe(last), Zlan(last), and Zvis(last) were defined as the age-gender-education-visit-adjusted robust Z-scores for the last available visit for each subject. The aMCI/AD group was defined as those participants whose adjusted Zmem was 1 IQR below the median at their last available visit, i.e., Zmem(last)≤−1.35. Converters were defined as that subset of the a MCI/AD group whose adjusted Zmem at baseline visit 0 was no more than 1 IQR below the median, i.e., Zmem(visit=0)>−1.35 and Zmem(last)≤−1.35. Participants were classified as NC if they had central scores on all domains at both the first and last visits, i.e., only if they met all of the following six conditions: (i) −1<Zmem(last)<1, (ii) −1<Zmem(visit=0)<1, (iii) Zmin(last)>−1.35, (iv) Zmin(visit=0)>−1.35, (v) Zmax(last)<1.35, and (vi) Zmax(visit=0)<1.35, where Zmax(last) and Zmax(visit=0) denote the maximum of the five adjusted Z-scores at the last and first visits, respectively. Zmem for normal participants had to be within 0.74 IQR (1 SD) of the median, rather than just 1 IQR (1.35 SD), to guarantee that they were >0.25 IQR (0.35 SD) from aMCI/AD participants.
- After three years of being in the study, (December, 2010), 202 participants had completed a baseline and two yearly visits. At the third visit, 53 participants met criteria for aMCI/AD and 96 met criteria for NC. Of the 53 aMCI/AD participants, 18 were Converters and 35 were incident aMCI or AD. The remaining 53 participants did not meet the criteria for either group and were not considered for biomarker profiling. Some of these individuals met criteria for non-amnestic MCI and many had borderline or even above average memory scores that precluded their inclusion as either a MCI/AD or NC. 53 of the NC participants were matched to the 53 aMCI/AD participants based on sex, age, and education level. Blood samples were obtained on the last available study visit for the 53 MCI/AD and the 53 NC for biomarker discovery. Two blood samples from each of the 18 Converters were also included: one from the baseline visit (Converterpre) when Zmem was non-impaired and one from the third visit (Converterpost) when Zmem was impaired and they met criteria for either aMCI or AD. Thus, at total of 124 samples from 106 participants were analyzed.
- Internal cross-validation was employed to validate findings from the discovery phase. Blood samples for validation were identified at the end of the fifth year of the study and all 106 participants included in the discovery phase were excluded from consideration for the validation phase. Cognitive composite Z-scores were re-calculated based on the entire sample available and the same procedure and criteria were used to identify samples for the validation phase. A total of 145 participants met criteria for a group: 21aMCI/AD and 124 NC. Of the 21 aMCI/AD, 10 were Converters. 20 of the NC participants were matched to the aMCI/AD participants on the basis of age, sex, and education level as in the discovery phase. In total, 41 participants contributed samples to the validation phase and, as before, the 10 Converters also contributed a baseline sample (Converterpre) for a total of 51 samples.
- Neurocognitive Statistical Analyses
- The neurocognitive analyses were designed to demonstrate the general equivalence of the discovery and validation samples on clinical and cognitive measures. Separate Multivariate Analysis of Variance (MANOVA's) tests were used to examine discovery/validation group performance on the composite Z-scores and on self-report measures of memory complaints, memory related functional impairment, depressive symptoms, and a global measure of cognitive function. In the first MANOVA, biomarker sample (discovery, validation) was the independent variable and MMQ, IADL, GDS, and MMSE were the dependent variables. In the second MANOVA, biomarker sample (discovery, validation) was the independent variable and the five cognitive domain Z-scores (Zatt, Zexe, Zlan,Zmem, and Zvis) were the dependent variables. Significance was set at alpha=0.05 and Tukey's HSD procedure was used for post-hoc comparisons. All statistical analyses were performed using SPSS (version 21).
- Lipidomics Methods
- LC/MS-grade acetonitrile (ACN), Isopropanol (IPA), water and methanol were purchased from Fisher Scientific (New Jersey, USA). High purity formic acid (99%) was purchased from Thermo-Scientific (Rockford, Ill.). Debrisoquine, 4-Nitrobenzoic acid (4-NBA), Pro-Asn, Glycoursodeoxycholic acid, Malic acid, were purchased from Sigma (St. Louis, Mo., USA). All lipid standards including 14:0 LPA, 17:0 Ceramide, 12:0 LPC, 18:0 Lyso PI and PC(22:6/0:0) were procured from Avanti Polar Lipids Inc. (USA).
- Metabolite Extraction
- Briefly, the plasma samples were thawed on ice and vortexed. For metabolite extraction, 25 μL of plasma sample was mixed with 175 μl of extraction buffer (25% acetonitrile in 40% methanol and 35% water) containing internal standards [10 μl of debrisoquine (1 mg/mL), 50 μL of 4, nitro-benzoic acid (1 mg/mL), 27.3 μl of Ceramide (1 mg/mL) and 2.5 μL of LPA (lysophosphatidic acid) (4 mg/mL) in 10 mL). The samples were incubated on ice for 10 minutes and centrifuged at 14,000 rpm at 4° C. for 20 minutes. The supernatant was transferred to a fresh tube and dried under vacuum. The dried samples were reconstituted in 200 μL of buffer containing 5% methanol, 1% acetonitrile and 94% water. The samples were centrifuged at 13,000 rpm for 20 minutes at 4° C. to remove fine particulates. The supernatant was transferred to a glass vial for UPLC-ESI-Q-TOF-MS analysis.
- UPLC-ESI-QTOF-MS Based Data Acquisition for Untargeted Lipidomic Profiling
- Each sample (2 μL) was injected onto a reverse-phase CSH C18 1.7 μM 2.1×100 mm column using an Acquity H-class UPLC system (Waters Corporation, USA). The gradient mobile phase comprised of water containing 0.1% formic acid solution (Solvent A), 100% acetonitrile (Solvent B) and 10% acetonitrile in isopropanol (IPA) containing 0.1% formic acid and 10 mM Ammonium formate (Solvent C). Each sample was resolved for 13 minutes at a flow rate of 0.5 mL/min for 8 min and then 0.4 mL/min from 8 to 13 min. The UPLC gradient consisted of 98% A and 2% B for 0.5 min then a ramp of curve 6 to 60% B and 40% A from 0.5 min to 4.0 min, followed by a ramp of curve 6 to 98% B and 2% A from 4.0 to 8.0 min, then ramped to 5% B and 95% C from 9.0 min to 10.0 min at a flow rate of 0.4 ml/min, and finally to 98% A and 2% B from 11.0 min to 13 minutes. The column eluent was introduced directly into the mass spectrometer by electrospray ionization. Mass spectrometry was performed on a Quadrupole-Time of Flight (Q-TOF) instrument (Xevo G2 QTOF, Waters Corporation, USA) operating in either negative (ESI−) or positive (ESI+) electrospray ionization mode with a capillary voltage of 3200 V in positive mode and 2800 V in negative mode, and a sampling cone voltage of 30 V in both modes. The desolvation gas flow was set to 750 Lh−1 and the temperature was set to 350° C. while the source temperature was set at 120° C. Accurate mass was maintained by introduction of a lock spray interface of leucine-enkephalin (556.2771 [M+H]+ or 554.2615 [M−H]−) at a concentration of 2 pg/μl in 50% aqueous acetonitrile and a rate of 2 μl/min. Data were acquired in centroid MS mode from 50 to 1200 m/z mass range for TOF-MS scanning as single injection per sample and the batch acquisition was repeated to check experimental reproducibility. For the metabolomics profiling experiments, pooled quality control (QC) samples (generated by taking an equal aliquot of all the samples included in the experiment) were run at the beginning of the sample queue for column conditioning and every ten injections thereafter to assess inconsistencies that are particularly evident in large batch acquisitions in terms of retention time drifts and variation in ion intensity over time. This approach has been recommended and used as a standard practice by leading metabolomics researchers. A test mix of standard metabolites was run at the beginning and at the end of the run to evaluate instrument performance with respect to sensitivity and mass accuracy. The overlay of the total ion chromatograms of the quality control samples depicted excellent retention time reproducibility. The sample queue was randomized to remove bias. The TICs for each of the three groups showed characteristic patterns.
- Stable Isotope Dilution—Multiple Reaction Monitoring Mass Spectrometry (SID-MRM-MS)
- Targeted metabolomic analysis of plasma sample was performed using the Biocrates Absolute-IDQ P180 (BIOCRATES, Life Science AG, Innsbruck, Austria). This validated targeted assay allows for simultaneous detection and quantification of metabolites in plasma samples (10 μL) in a high throughput manner. The methods have been described in detail. The plasma samples were processed as per the instructions by the manufacturer and analyzed on a triple quadrupole mass spectrometer (Xevo TQ-S, Waters Corporation, USA) operating in the MRM mode. The measurements were made in a 96 well format for a total of 148 samples, seven calibration standards and three quality control samples were integrated in the kit.
- Briefly, the flow injection analysis (FIA) tandem mass spectrometry (MS/MS) method was used to quantify a panel of 144 lipids simultaneously by multiple reaction monitoring. Absolute quantification was achieved by extrapolating from a standard curve. The other metabolites were resolved on the UPLC and quantified using scheduled MRMs. The kit facilitated absolute quantitation of 21 amino acids, hexose, carnitine, 39 acylcarnitines, 15 sphingomyelins, 90 phosphatidylcholines and 19 biogenic amines. Data analysis was performed using the MetIQ software (Biocrates) while the statistical analyses were performed using the STAT pack module v3 (Biocrates). The abundance was calculated from area under the curve by normalizing to the respective isotope labeled internal standard. The concentration is expressed as nmol/L. Quality control samples were used to assess reproducibility of the assay. The mean of the coefficient of variation (CV) for the 180 metabolites was 0.08 and 95% of the metabolites had a CV of <0.15.
- Lipidomics Statistical Analyses
- The m/z features of metabolites were normalized with log transformation that stabilized the variance followed with a quantile normalization to make the empirical distribution of intensities the same across samples. The metabolites were selected among all those known to be identifiable using a ROC regularized learning technique, based on the least absolute shrinkage and selection operator (LASSO) penalty as implemented with the R package ‘glmnet’, which uses cyclical coordinate descent in a pathwise fashion. The regularization path over a grid of values was obtained for the tuning parameter lambda through 10-fold cross-validation. The optimal value of the tuning parameter lambda, which was obtained by the cross-validation procedure, was then used to fit the model. All the features with non-zero coefficients were retained for subsequent analysis. The classification performance of the selected metabolites was assessed using area under the ROC (receiver operating characteristic) curve (AUC). The ROC can be understood as a plot of the probability of classifying correctly the positive samples against the rate of incorrectly classifying true negative samples. Thus the AUC measure of an ROC plot is actually a measure of predictive accuracy. To maintain rigor of independent validation, the simple logistic model with the ten metabolite panel was used, although a more refined model can yield greater AUC.
- Results
- Over the course of the study, 74 participants met criteria for either aMCI or mild AD, 46 of these were incidental cases at entry and 28 phenoconverted (Converters) from a non-impaired memory status at entry (Converterpre). The average time to phenoconversion was 2.1 years (range=1-5 years). 53 a MCI/AD participants were selected, including 18 Converters, and 53 age-, education-, and sex-matched cognitively normal control (NC) participants for untargeted lipidomics biomarker discovery. Internal cross validation was used to evaluate the accuracy of the discovered PUFA profile in classifying a blinded sample of 51 subjects consisting of the remaining subset of 21 aMCI/AD participants, including 10 Converters, and an additional 20 matched NC.
- The aMCI/AD, Converter, and NC groups were defined primarily using a composite measure of memory performance in addition to composite measures of other cognitive abilities and clinical measures of memory complaints and functional capacities. (See Tables 1 and 2).
-
TABLE 2 Dependent Measure Domain Clinical/Cognitive Measures (Range) Assessed Multiple Assessment Inventory IADL Scale (MAI-IADL) Total Score Functional Lawton M P. (1988) Instrumental Activities of Daily Living (0-27) capacities (IADL) scale: Original observer-rated version. Psychonharmacology Bulletin, 24, 785-7. Multifactorial Memory Questionnaire (MMQ) Total Score Memory Troyer A K and Rich J B. (2002). Psychometric (0-228) complaints properties of a new metamemory questionnaire for older adults. Journal of Gerontology, 57(1), 19-27. Mini Mental State Examination (MMSE) Total Score Global Folstein, M F, Folstein, S E, and McHugh, P R. (1975). “Mini- (0-30) cognitive mental state”. Journal of Psychiatric Research, 12, 189-98. ability Geriatric Depression Scale-Short Form (GDS-SF) Total Score Mood Sheikh J I and Yesavage J A. (1986). Geriatric Depression (0-15) Scale (GDS): Recent evidence and development of a shorter version. Clinical Gerontologist, 5, 165-173. Wechsler Memory Scale-III Forward Digit Span Span Length Attention (WMS-III FDS) (0-9) Wechsler D. Wechsler Memory Scale-III Manual. San Antonio, TX: The Psychological Corporation, 1997. Trail Making Test- Part A (TMT-A) Completion Attention Reitan R M. (1958). Validity of the Trail Making Test as an time indicator of organic brain damage. (1-300 seconds) Perceptual and Motor Skills, 8, 271-6. Wechsler Memory Scale-III Backward Digit Span Span Length Executive (WMS-III BDS) (0-8) ability Wechsler D. Wechsler Memory Scale-III Manual. San Antonio, TX: The Psychological Corporation, 1997. Trail Making Test- Part B (TMT-B) Completion Executive Reitan R M. (1958). Validity of the Trail Making Test as an Time ability indicator of organic brain damage. (1-300 seconds) Perceptual and Motor Skills, 8, 271-6. Category fluency (Animals) Animals Language Borkowski J, Benton A, Spreen O. (1967). Word fluency and named in brain damage. Neuropsychologia, 5, 135-140 1-minute Boston Naming Test 60-Item version (BNT-60) Total Correct Language Kaplan E, Goodglass H, and Weintraub S. (1983). Boston (0-60) Naming Test. Philadelphia: Lea & Feibiger. Rey Auditory Verbal Learning Test Learning Total words Verbal (RAVLT Learning) Rey A. (1964). L'examen clinique en recalled over Trials learning psychologie. Paris: Presses Universitaires de France. 1-5 (0-75) Rey Auditory Verbal Learning Test Recall Words recalled Verbal (RAVLT Retrieval) Rey A. (1964). L'examen clinique en at 20-minute delay retrieval psychologie. Paris: Presses Universitaires de France. (0-15) Rey Auditory Verbal Learning Test Retention True positives- Verbal (RAVLT Recognition) Rey A. (1964). L'examen clinique en false positives retention psychologie. Paris: Presses Universitaires de France. (0-15) Hooper Visual Organization Test (HVOT) Total score Visuoperception Hooper H E. Hooper Visual Organization Test (VOT) Los (0-30) Angeles: Western Psychological Services; 1983. - Plots of group means on the composite measures can be found in
FIG. 1 and group means are reported in Table 3. The discovery and validation groups did not differ on clinical measures including self-reported memory complaints, functional impairment, depressive symptoms, and a global measure of cognition (F(4,170)=1.376, p=0.244), nor on any composite Z-score (F(5,169)=2.118, p=0.066) demonstrating the general equivalence of the participants used for the discovery and validation phases of the biomarker analysis. -
TABLE 3 Normal Control Converterpre MCI/AD Cognitive Measure (n = 73) (n = 28) (n = 74) Multiple Assessment Inventory 26.51 (1.71) 26.65 (0.87) 24.82 (3.60) IADL Scale (MAI-IADL ) Multifactorial Memory 130.32 (19.93) 139.71 (13.36) 121.01 (18.14) Questionnaire (MMQ) Mini Mental State 28.64 (1.30) 28.61 (2.49) 26.32 (2.87) Examination (MMSE) Geriatric Depression Scale-Short 1.47 (2.02) 1.32 (2.28) 1.97 (2.7) Form (GDS-SF) Wechsler Memory Scale-III Forward 6.25 (1.05) 6.18 (0.95) 6.14 (1.13) Digit Span (WMS-III FDS) Trail Making Test- Part A (TMT-A) 36.69 (13.23) 46.14 (14.75) 55.26 (44.63) Wechsler Memory Scale-III Backward 4.34 (0.9) 4.29 (0.76) 4.01 (0.91) Digit Span (WMS-III BDS) Trail Making Test- Part B (TMT-B) 98.53 (41.30) 134.57 (63.89) 151.99 (69.82) Category fluency (Animals) 20.91 (4.72) 19.0 (5.24) 15.16 (5.03) Boston Naming Test 60-ltem 56.29 (3.19) 53.14 (7.96) 50.51 (9.46) version (BNT-60) Rey Auditory Verbal Learning Test 43.43 (7.6) 37.0 (5.88) 27.08 (7.01) Learning (RAVLT Total Learning A1-A5) Rey Auditory Verbal Learning Test 7.84 (2.48) 5.32 (2.59) 1.93 (1.64) Delayed Recall (RAVLT Trial A7) Rey Auditory Verbal Learning Test 13.30 (1.57) 11.14 (2.24) 7.09 (3.15) Retention (RAVLT Recognition) Hooper Visual Organization 23.96 (3.05) 22.36 (3.72) 20.93 (4.51) Test (HVOT) - Lipidomic Definition of Participant Groups
- The plasma samples from the 124 discovery phase participants were subjected to lipidomics analysis. In the discovery phase, metabolomic/lipidomic profiling yielded 2700 features in the positive mode and 1900 features in the negative mode. The metabolites that define the participant groups were selected from among all known to be identifiable using a regularized learning technique, the least absolute shrinkage and selection operator (LASSO) penalty as implemented with the R package ‘glmnet’. The LASSO analysis revealed features that assisted in unambiguous class separation between a MCI/AD, Converterpre and the NC group (Table 4).
-
TABLE 4 Putative metabolite markers resulting from binary comparison of the study groups Lasso Comparison Mass/Charge Metabolite Coefficient Groups Mode Ratio PI(18:0/0:0) ↓ (−0.674) Normal vs NEG 599.3226 Converterpre Pro Asn ↑ (0.192) Normal vs POS 230.1146 aMCI/AD Glycoursodeoxycholic ↑ (0.107) Normal vs POS 450.3196 acid aMCI/AD Malic acid ↓ (−0.024) Normal vs POS 134.0207 aMCI/AD - The markers in Table 1 were chosen based on the significant predictive value as determined by LASSO coefficient analysis. The positive estimated LASSO coefficient suggests elevation in corresponding comparison group (a MCI/AD and Converterpre) compared to normal control (NC) participants. Up arrows indicate up-regulation in the comparison group as compared to the NC participants while the down arrow suggests down-regulation in these groups.
- This untargeted lipidomic analysis revealed a significant decrease in the level of phosphatidyl inositol (PI) in the Converterpre group and an elevation in the plasma levels of glycoursodeoxycholic acid in the a MCI/AD patients as compared to the NC group. These metabolites were unambiguously identified using tandem mass spectrometry. The other metabolites that displayed differential abundance in the study groups consisted of amino acids, biogenic amines and a broad range of phospholipids and other lipid species that were putative identified based on accurate mass stringency of ≤5 ppm.
- In the next step of the metabolomic/lipidomic analyses, multiple reaction monitoring (MRM) was performed for stable isotope dilution-mass spectrometry (SID-MS) to unambiguously identify and quantify those metabolites such as lipids, amino acids and biogenic amines that function similar to those identified in the LASSO analysis and characterize the participant groups, with special emphasis on differences that would predict a predisposition of phenoconversion from NC to aMCI/AD. The data revealed significantly lower plasma levels of serotonin, taurine, phenylalanine, proline, lysine, phosphatidyl choline (PC) and acylcarnitine (AC) in Converterpre participants who later developed a MCI/AD. Conversely, these participants also showed an elevation in the levels of DOPA.
-
TABLE 5 Difference detection of putative metabolites using stable isotope dilution multiple reaction monitoring mass spectrometry (SID-MRM-MS). Fold Comparison Metabolite Change Groups Mode p-value PC ae C38:4 ↓ Normal vs POS 0.00417 Converterpre Proline ↓ Normal vs POS 3.00E−05 Converterpre Lysine ↓ Normal vs POS 0.0020 Converterpre Serotonin ↓ Normal vs POS 0.0160 Converterpre Taurine ↓ Normal vs POS 0.0030 Converterpre DOPA ↑ Normal vs POS 0.0001 Converterpre Phenylalanine ↓ Normal vs POS 1.00E−05 Converterpre Acylcarnitine C7-DC ↓ Normal vs POS 0.0001 aMCI/AD - Up arrows in Table 5 indicate up-regulation in the comparison group as compared to the normal control (NC) participants while the down arrow suggests down-regulation in these groups.
- The targeted metabolomic/lipidomic analysis identified of a set of ten metabolites, comprised of PCs, lyso PCs, and ACs that were depleted in the plasma of the Converterpre participants compared to the NC group. These metabolites remain depleted after the same participants phenoconverted to aMCI/AD (Converterspost) and were nearly equivalent to the low levels seen in the cognitively impaired a MCI/AD group. A simple logistic model with the ten metabolite panel was used to predict/classify Converterpre and NC participants. When displayed as a ROC curve, the ten metabolite panel comparing Converterpre and NC participants yielded an AUC of 0.96, while the panel yielded an AUC of 0.827 for the aMCI/AD vs NC classification.
- To confirm the reproducibility of the ten metabolite panel from the discovery samples, targeted quantitative metabolomics/lipidomics analyses was performed using plasma from the independent validation group of 40 participants as an independent cross validation. One sample from the MCI/AD group was not available for lipidomic analysis. The validation samples were obtained from the last available visit from the a MCI/AD, Converterpre, and NC groups and were designated as groups A, B, and C and analyzed in a blinded fashion, without specification of diagnostic identities. The samples were processed and analyzed using the same SID-MRM-MS technique as in the discovery phase. The blinded data were analyzed to determine if the unknown groups could be characterized into the correct diagnostic categories based solely on the levels of the ten metabolite panel. The validation analysis revealed lower levels of the assayed metabolites in groups A and B compared to group C. Based on these qualitative differences, it was predicted that group C was the NC group and groups A and B were Converterpre and aMCI/AD groups, respectively. Subsequent un-blinding of the groups confirmed these predictions.
- The metabolomic data was used from the untargeted LASSO analysis to build separate linear classifier models that would distinguish the aMCI/AD group from the NC group and the Converterpre group from the NC group. A receiver operating characteristic (ROC) analysis was employed to determine the area under the ROC curve (AUC) to assess the performance of the classifier models in differentiating the groups. When distinguishing between the Converterpre and NC groups, the LASSO identified metabolites yielded an AUC of 0.96, and 0.83 when distinguishing the aMCI/AD and NC groups. These high AUC values demonstrate robust discrimination between the aMCI/AD, Converterpre, and NC groups by the models. Using the same linear classifier method, a simple logistic model was constructed using just the ten metabolite panel and used this to classify the same groups. When displayed as a ROC curve, the ten metabolite panel classified Converterpre and NC participants with an AUC of 0.96, while the panel yielded an AUC of 0.827 for the aMCI/AD vs NC classification.
- The effect of apolipoprotein E (APOE) genotype was considered. ApoE protein is involved in lipid transport/metabolism and APOE allele status, including homozygous (ε2/2 vs. ε3/3 vs. ε4/4) and heterozygous (ε2/3 vs. ε2/4 vs. ε3/4) options, alter the risk for Alzheimer's Disease (AD). With the presence of at least a single APOE ε4 allele increasing the risk for AD (with an even greater risk with ε4/4), risk status was accounted for by repeating this classification analysis with the −ε4 allele presence as a covariate. This latter analysis found the classification accuracy changed only minimally from 0.96 to 0.968 (p=0.992). Furthermore, a classifier model using only APO −ε4 produced an AUC of 0.54 for classifying the Converterpre and NC groups implying virtually random classification. These findings clearly indicate that the presumed pathophysiology reflected by the ten metabolite biomarker panel is independent of ApoE mediated effects. Finally, the same simple logistic classifier model developed for the discovery samples was applied to the independent validation samples. The ROC constructed from the validation group data classified Converterpre and NC participants with an AUC of 0.92 and 0.77 for classifying the aMCI/AD vs NC groups. For a specificity of 90%, the ten metabolite panel yielded a sensitivity of 83.3% for correct classification of the Converterpre and NC participants in the discovery phase and a sensitivity of 90% in the validation phase.
- Methods for Preclinical Alzheimer's Disease Index (PADI)
- All participants were community-dwelling, older adults from the greater Rochester, N.Y. and Irvine, Calif. communities. Participants were recruited through local media (newspaper and television advertisements), senior organizations, and word of mouth. Inclusion criteria included age 70 or older, proficiency with written and spoken English and corrected vision and hearing necessary to complete the cognitive battery. Participants were excluded for the presence of known major psychiatric or neurological illness (including Alzheimer's disease or MCI, cortical stroke, epilepsy, and psychosis) at time of enrollment, current or recent (<1 month) use of anticonvulsants, neuroleptics, HAART, antiemetics, and antipsychotics for any reason, and serious blood diseases including chronic abnormalities in complete blood count and anemia requiring therapy and/or transfusion.
- Operationalizing Groups
- Alzheimer's disease is a cognitive disorder defined in numerous diagnostic schemes by a primary impairment in memory. The classification of preclinical Alzheimer's disease via PADI relies heavily on the assessment of memory, but it is recognized that the preclinical state may also involve other cognitive domains, thus the methods disclosed herein rely on assessing all primary cognitive domains (Table 6). The primary Memory outcome was based on the Rey Auditory Visual Learning Test (RAVLT). Learning was defined as the sum of the number of correct words recalled over the 5 learning trials; Retrieval was defined as the total number of correct words recalled from trial A7; and Retention was defined as the total number correct words recognized minus the number of false positives. Each of these three sub-scores (Learning, Retrieval, and Retention) was converted to an empirical Z-score by subtracting its sample mean and dividing by its sample SD. The three resulting positively correlated RAVLT-based Z-scores were then averaged to form the composite Memory score (Zmem). So defined, Zmem was approximately normal with mean 0, SD<1, and some negative skewness attributable to the fact that healthy participants often score at or near the upper bounds, especially for Retention. The Attention (Zatt), Executive (Zexe), and Language (Zlan) scores were each defined as averages of empirical Z-score transforms of pairs of subscores, as follows. Zatt: (1) completion time (in seconds, truncated at 300 s) for the Trail Making Test Part A and (2) the Wechsler Memory Scale-Ill Forward Digit Span; Zexe: (1) completion time (in seconds, truncated at 300 s) for the Trail Making Test Part B and (2) the Wechsler Memory Scale-Ill Backward Digit Span; Zlan: (1) total score (out of 60) for the Boston Naming Test and (2) Category Fluency (Animals Named in 1 minute). The Visuoperceptual score (Zvis) was simply the empirical Z-transform of the Total Score (out of 30) for the Hooper Visual Organization Test (HVOT), which itself was approximately normally distributed. See Table 2 for composite Z score components.
- Standardization and Adjustment for Age, Gender, Education, and Visit
- Linear Generalized Estimating Equation (GEE) models were used to model each of the five cognitive domains (Memory, Attention, Executive, Language, and Visuospatial) as a function of age, gender, education, and visit number, using a homoscedastic working independence covariance matrix, i.e., least squares was used to estimate all linear model coefficients based on the pooled data from all available visits. Since Memory was the focal cognitive domain, the functional form for the covariates was selected to best model Memory, and exactly the same functional form was used for the other four cognitive domains. Given the evidence of nonlinearity, the effect of education was modeled using a continuous piecewise linear spline with knots at 12, 14, and 16 years of education. Memory increased with years of education between 5-12 years, decreased between 12-14 years, increased again between 14-16 years, and then nearly leveled off for 16-23 years. Age was modeled linearly, as there was insufficient evidence to support nonlinearity via piecewise linear spline knots or a quadratic component, yet Memory scores decreased linearly with age. Visit was modeled via an indicator for baseline visit 0, given that there was insufficient evidence that subsequent visits differed from each other, yet there was evidence that subsequent visits had higher Memory scores compared with baseline visit 0. Gender was modeled via an indicator for males, who had lower memory scores than females. There was insufficient evidence to support any interactions. Residuals from each model were then robustly standardized to have median 0 and robust SD=1, where the robust SD=IQR/1.35, as 1.35 is the IQR (Inter-Quartile Range) of a standard normal distribution. The choice to use robust measures of location (median) and dispersion (IQR) was made to reduce the influence that cognitively impaired participants might have on the mean and SD, and in recognition of the slight negative skewness of the residuals. The robustly standardized residuals were then viewed as age-gender-education-visit-adjusted robust Z-scores for each of the five cognitive domains.
- Defining aMCI/AD, Converters, and NC
- For each subject, Zmem(last), Zatt(last), Zexe(last), Zlan(last), and Zvis(last) were defined as the age-gender-education-visit-adjusted robust Z-scores for the last available visit for each subject. The aMCI/AD group was defined as those participants whose adjusted Zmem was 1 IQR below the median at their last available visit, i.e., Zmem(last)≤−1.35. Converters were defined as that subset of the MCI/AD group whose adjusted Zmem at baseline visit 0 was no more than 1 IQR below the median, i.e., Zmem(visit=0)>−1.35 and Zmem(last)≤−1.35. Participants were classified as NC if they had central scores on all domains at both the first and last visits, i.e., only if they met all of the following six conditions: (i) −1<Zmem(last)<1, (ii) −1<Zmem(visit=0)<1, (iii) Zmin(last)>−1.35, (iv) Zmin(visit=0)>−1.35, (v) Zmax(last)<1.35, and (vi) Zmax(visit=0)<1.35, where Zmax(last) and Zmax(visit=0) denote the maximum of the five adjusted Z-scores at the last and first visits, respectively. Zmem for normal participants had to be within 0.74 IQR (1 SD) of the median, rather than just 1 IQR (1.35 SD), to guarantee that they were >0.25 IQR (0.35 SD) from aMCI/AD participants.
- Frequency Matching aMCI/AD and NC on Age, Education, and Sex
- Comparing the distributions of age, education, and sex for participants classified as a MCI/AD and NC it was observed that NC participants were younger. Given this, and given budget limitations for genetic profiling, NC participants were frequency matched to the aMCI/AD participants for each of the Discovery and Validation samples based on age, education, and sex. This was accomplished by stratifying the sample by four groups of age at the last visit (75-79, 80-85, 86-94, 95-100), three education groups (5-12, 13-18, 19-23), and two sexes (male, female), resulting in 24 age-education-sex strata. An equal number of NC participants were randomly selected to match the aMCI/AD participants per the strata for the Discovery sample, and because one of the strata did not contain a sufficient number of NC participants, the Validation sample had one less NC subject than the a MCI/AD group.
- Derivation of the Preclinical Alzheimer's Disease Index (PADI)
- For the development of the preclinical Alzheimer's disease Index (PADI), only cognitively normal participants were included at entry (+0.7 SD from the group mean on all domain z-scores) who subsequently either phenoconverted to amnestic MCI or LOAD (Converters, n=28) or remained cognitively normal (NC, n=73) over the course of the study. Time to phenoconversion averaged 2.1 years. The baseline characteristics of the Converter and NC groups were similar except in three cognitive domains: attention, executive function, and memory (Table 6). Stepwise logistic regression revealed that only the attention (OR=0.247, 95% CI: 0.09-0.68) and memory (OR=0.232, 95% CI: 0.10-0.54) z-scores were significant predictors of group. The PADI was constructed by combining the two domains (weighted −0.484 for attention and −0.516 for memory) such that higher scores indicate poorer cognitive performance.
- The utility of the PADI was tested in the remaining study participants (n=515), to identify phenoconversion risk in subjects not impaired at baseline, but who exhibited subtle deficits that did not allow their consideration as “normal”. A total of 35 of the latter met criteria for MCI or AD an average of 1.9 years later. The baseline PADI distinguished these at risk individuals from the rest (ROC AUC=0.93, 95% CI: 0.90, 0.97). Survival analysis, controlling for age, years of education, APOE4 status, global cognition, depression, and subjective memory complaints was also significant (HR=4.57, 95% CI=3.47, 6.01) (
FIG. 2 ). -
TABLE 6 Cognitive Measures: Means and Standard Deviations Dependent Normal Measure Domain Control Converterpre aMCI/AD Clinical/Cognitive Measures (Range) Assessed (n = 73) (n = 28) (n = 74) Multiple Assessment Inventory IADL Scale (MAI-IADL) Total Score Functional 26.51 (1.71) 26.65 (0.87) 24.82 (3.60) Lawton M P. (1988) Instrumental Activities of Daily (0-27) capacities Living (IADL) scale: Original observer-rated version. Psychopharmacology Bulletin, 24, 785-7. Multifactorial Memory Questionnaire (MMQ) Total Score Memory 130.32 (19.93) 139.71 (13.36) 121.01 (18.14) Troyer A K and Rich J B. (2002). Psychometric (0-228) complaints properties of a new metamemory questionnaire for older adults. Journal of Gerontology, 57(1), 19-27. Mini Mental State Examination (MMSE) Total Score Global 28.64 (1.30) 28.61 (2.49) 26.32 (2.87) Folstein, M F, Folstein, S E, and McHugh, P R. (1975). (0-30) cognitive “Mini-mental state”. ability Journal of Psychiatric Research, 12, 189-98. Geriatric Depression Scale-Short Form (GDS-SF) Total Score Mood 1.47 (2.02) 1.32 (2.28) 1.97 (2.7) Sheikh J I and Yesavage J A. (1986). Geriatric (0-15) Depression Scale (GDS): Recent evidence and development of a shorter version. Clinical Gerontologist, 5, 165-173. Wechsler Memory Scale-III Forward Digit Span Span Length Attention 6.25 (1.05) 6.18 (0.95) 6.14 (1.13) (WMS-III FDS) Wechsler D. Wechsler Memory Scale-III (0-9) Manual. San Antonio, TX: The Psychological Corporation, 1997. Trail Making Test- Part A (TMT-A) Completion Attention 36.69 (13.23) 46.14 (14.75) 55.26 (44.63) Reitan R M. (1958). Validity of the Trail Making time Test as an indicator of organic brain damage. (1-300 sec) Perceptual and Motor Skills, 8, 271-6. Wechsler Memory Scale-III Backward Digit Span Span Length Executive 4.34 (0.9) 4.29 (0.76) 4.01 (0.91) (WMS-III BDS) Wechsler D. Wechsler Memory Scale-III (0-8) ability Manual. San Antonio, TX: The Psychological Corporation, 1997. Trail Making Test- Part B (TMT-B) Completion Executive 98.53 (41.30) 134.57 (63.89) 151.99 (69.82) Reitan R M. (1958). Validity of the Trail Making Test Time ability as an indicator of organic brain damage. (1-300 sec) Perceptual and Motor Skills, 8, 271-6. Category fluency (Animals) Animals Language 20.91 (4.72) 19.0 (5.24) 15.16 (5.03) Borkowski J, Benton A, Spreen O. (1967). Word fluency named in 1- and brain damage. Neuropsychologia, 5, 135-140 minute Boston Naming Test 60-ltem version (BNT-60) Total Correct Language 56.29 (3.19) 53.14 (7.96) 50.51 (9.46) Kaplan E, Goodglass H, and Weintraub S. (1983). (0-60) Boston Naming Test. Philadelphia: Lea & Feibiger. Rey Auditory Verbal Learning Test Learning Total words Verbal 43.43 (7.76) 37.0 (5.88) 27.08 (7.01) (RAVLT Learning) Rey A. (1964). L'examen clinique en recalled over learning psychologie. Paris: Presses Universitaires de France. Trials 1-5 (0-75) Rey Auditory Verbal Learning Test Recall Words Verbal 7.84 (2.48) 5.32 (2.59) 1.93 (1.64) (RAVLT Retrieval) Rey A. (1964). L'examen clinique en recalled at 20- retrieval psychologie. Paris: Presses Universitaires de France. minute delay (0-15) Rey Auditory Verbal Learning Test Retention True pos. - Verbal 13.30 (1-57) 11.14 (2.24) 7.09 (3.15) (RAVLT Recognition) Rey A. (1964). L'examen clinique en false pos. retention psychologie. Paris: Presses Universitaires de France. (0-15) Hooper Visual Organization Test (HVOT) Total score Visuo- 23.96 (3.05) 22.36 (3.72) 20.93 (4.51) Hooper H E. Hooper Visual Organization Test (VOT) (0-30) perception Los Angeles: Western Psychological Services; 1983. -
TABLE 7 PADI Baseline Demographic and Health Characteristics. NC Converter t or χ2 value, (n = 73) (n = 28) df (p) Age, M (SD) 80.03 (3.63) 79.86 (4.21) 0.18, 89 (.86) Male, n (%) 27 (39.1%) 10 (45.5%) 0.28, 1 (.60) Years of education, 15.52 (2.37) 15.18 (2.84) 0.56, 89 (.58) M (SD) APOE4 carrier, n (%) 16 (23.2%) 4 (18.2%) 0.24, 1 (.62) Depression, M (SD) 1.28 (1.99) 1.41 (2.50) −0.26, 89 (.80) Memory complaints, 26.61 (0.79) 26.59 (0.96) 0.09, 89 (.93) M (SD) Global cognition, 28.86 (1.18) 28.68 (2.68) 0.43, 89 (.67) M (SD) Attention, M (SD) 0.03 (0.51) −0.36 (0.59) 3.24, 94 (.002) Executive function, −0.08 (0.56) −0.49 (0.89) 2.31, 35 (.027) M (SD) Language, M (SD) 0.11 (0.52) −0.22 (1.01) 1.61, 30 (.12) Memory, M (SD) 0.11 (0.65) −0.40 (0.75) 3.41, 99 (.001) Visuoperception, 0.22 (0.68) −0.10 (1.04) 1.50, 37 (.14) M (SD) Note. Depression was measured using 15-item Geriatric Depression Scale; Memory complaints were measured using the Multifactorial Memory Questionnaire; Global cognition was measured using Mini Mental State Examination.
Claims (20)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/889,771 US20200363436A1 (en) | 2015-06-08 | 2020-06-01 | Methods of assessing future memory loss by measuring polyunsaturated fatty acids |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562172636P | 2015-06-08 | 2015-06-08 | |
US201562194223P | 2015-07-18 | 2015-07-18 | |
PCT/US2016/036397 WO2016200903A1 (en) | 2015-06-08 | 2016-06-08 | Methods of assessing future memory loss by measuring polyunsaturated fatty acids |
US201715580984A | 2017-12-08 | 2017-12-08 | |
US16/889,771 US20200363436A1 (en) | 2015-06-08 | 2020-06-01 | Methods of assessing future memory loss by measuring polyunsaturated fatty acids |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/580,984 Continuation US10670617B2 (en) | 2015-06-08 | 2016-06-08 | Methods of assessing future memory loss by measuring polyunsaturated fatty acids |
PCT/US2016/036397 Continuation WO2016200903A1 (en) | 2015-06-08 | 2016-06-08 | Methods of assessing future memory loss by measuring polyunsaturated fatty acids |
Publications (1)
Publication Number | Publication Date |
---|---|
US20200363436A1 true US20200363436A1 (en) | 2020-11-19 |
Family
ID=57504925
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/580,984 Active US10670617B2 (en) | 2015-06-08 | 2016-06-08 | Methods of assessing future memory loss by measuring polyunsaturated fatty acids |
US16/889,771 Abandoned US20200363436A1 (en) | 2015-06-08 | 2020-06-01 | Methods of assessing future memory loss by measuring polyunsaturated fatty acids |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/580,984 Active US10670617B2 (en) | 2015-06-08 | 2016-06-08 | Methods of assessing future memory loss by measuring polyunsaturated fatty acids |
Country Status (2)
Country | Link |
---|---|
US (2) | US10670617B2 (en) |
WO (1) | WO2016200903A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022226280A1 (en) * | 2021-04-23 | 2022-10-27 | Duke University | Ceramide and spingomyelin in neurological disorders |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115774059A (en) * | 2021-09-07 | 2023-03-10 | 中国科学院深圳先进技术研究院 | Alzheimer disease biomarker and screening method and application thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030211622A1 (en) * | 1998-06-29 | 2003-11-13 | Roberts L. Jackson | Methods and compositions to assess oxidative brain injury |
WO2007098020A2 (en) | 2006-02-16 | 2007-08-30 | Reliant Pharmaceuticals, Inc. | Methods of screening patients for omega-3 fatty acid therapy |
US20160209428A1 (en) * | 2013-08-21 | 2016-07-21 | The Regents Of The University Of California | Diagnostic and predictive metabolite patterns for disorders affecting the brain and nervous system |
-
2016
- 2016-06-08 US US15/580,984 patent/US10670617B2/en active Active
- 2016-06-08 WO PCT/US2016/036397 patent/WO2016200903A1/en active Application Filing
-
2020
- 2020-06-01 US US16/889,771 patent/US20200363436A1/en not_active Abandoned
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022226280A1 (en) * | 2021-04-23 | 2022-10-27 | Duke University | Ceramide and spingomyelin in neurological disorders |
Also Published As
Publication number | Publication date |
---|---|
US10670617B2 (en) | 2020-06-02 |
US20180196073A1 (en) | 2018-07-12 |
WO2016200903A1 (en) | 2016-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Karhson et al. | Plasma anandamide concentrations are lower in children with autism spectrum disorder | |
Li et al. | Plasma phospholipids and prevalence of mild cognitive impairment and/or dementia in the ARIC Neurocognitive Study (ARIC-NCS) | |
US11808774B2 (en) | Metabolic biomarkers for memory loss | |
Abdullah et al. | APOE ε4 specific imbalance of arachidonic acid and docosahexaenoic acid in serum phospholipids identifies individuals with preclinical Mild Cognitive Impairment/Alzheimer's Disease | |
Cui et al. | Metabolomics and incident dementia in older Chinese adults: The Shanghai Aging Study | |
EP3577455A1 (en) | Biomarkers for the diagnosis and characterization of alzheimer's disease | |
US20170242040A1 (en) | Method for the diagnosis of alzheimer's disease and mild cognitive impairment | |
US20200363436A1 (en) | Methods of assessing future memory loss by measuring polyunsaturated fatty acids | |
Zhao et al. | Metabolic profiles of biological aging in American Indians: The strong heart family study | |
US20170052204A1 (en) | Metabolic and Genetic Biomarkers for Memory Loss | |
US10578629B2 (en) | Biomarkers for memory loss | |
Setoyama et al. | Blood metabolic signatures of hikikomori, pathological social withdrawal | |
Amatruda et al. | Retrospective unbiased plasma lipidomic of progressive multiple sclerosis patients-identifies lipids discriminating those with faster clinical deterioration | |
US10890589B2 (en) | Metabolic biomarkers for memory loss | |
US11280797B2 (en) | Metabolic biomarkers for cognitive ability | |
US20170184613A1 (en) | Exosome and lipid biomarkers for memory loss | |
Sol et al. | Ischemia preconditioning induces an adaptive response that defines a circulating metabolomic signature in ischemic stroke patients | |
Dakterzada et al. | Cerebrospinal fluid neutral lipids predict progression from mild cognitive impairment to Alzheimer’s disease | |
Fu et al. | Circulating Amyloid-β and Methionine-Related Metabolites to Predict the Risk of Mild Cognitive Impairment: A Nested Case-Control Study | |
Zeleznik et al. | A Population-Based Study of Plasma Metabolomic Profiles of Persistent Tinnitus Identifies Candidate Biomarkers | |
KR102621049B1 (en) | Assessment methods and prognostic kit for predicting suicidal behaviors in patients with depressive disorders using multimodal serum biomarkers | |
Ortlund et al. | Integrative brain omics approach reveals key role for sn-1 lysophosphatidylethanolamine in Alzheimer's dementia | |
Kärkkäinen et al. | Alcohol use associated alterations in the circulating metabolite profile in the general population and in individuals with major depressive disorder | |
Han et al. | Association Between the Early Serum Lipid Metabolism Profile and Delayed Neurocognitive Recovery After Cardiopulmonary Bypass in Cardiac Surgical Patients: a Pilot Study | |
Wang et al. | Serum metabonomics as a diagnostic approach for cancer‑related fatigue |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE AFTER FINAL ACTION FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: ARMY/MRDC, MARYLAND Free format text: CONFIRMATORY LICENSE;ASSIGNOR:GEORGETOWN UNIVERSITY;REEL/FRAME:065617/0110 Effective date: 20231108 Owner name: NIH - DEITR, MARYLAND Free format text: CONFIRMATORY LICENSE;ASSIGNOR:GEORGETOWN UNIVERSITY;REEL/FRAME:065617/0110 Effective date: 20231108 |
|
AS | Assignment |
Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT, MARYLAND Free format text: CONFIRMATORY LICENSE;ASSIGNOR:GEORGETOWN UNIVERSITY;REEL/FRAME:066351/0356 Effective date: 20231106 |